NEP

N-ethylpentedrone

Sources

1 strong · 18 moderate · 6 weak

Studies and references cited across this article, graded by evidence strength.

Claims checked

84verified2partial6inconclusive4not supported

Inconclusive means the cited source neither confirms nor refutes the claim — a lower-confidence badge, not an error.

Generated

Apr 26, 2026 · pipeline-v5

Values approved

136/137 (99%)

Data points an editor reviewed and accepted for publication.

Value Provenance

Dosing

smoked

Predates provenance tracking — no derivation record for this dataset

Field	Published	AI Proposed
Threshold	5 mg	no record
Low	5–15 mg	no record
Common	15–30 mg	no record
Strong	30–50 mg	no record
Heavy	50+ mg	no record
Editorial	Carried forward from Curiosity v1 seed version during v1 history consolidation (2026-06-04).

insufflatedtrace

Field	Published	AI Proposed	Confidence
Threshold	5 mg	5 mg	medium
Low	10–20 mg	10–20 mg	medium
Common	20–40 mg	20–40 mg	medium
Strong	40–60 mg	40–60 mg	medium
Heavy	75+ mg	75+ mg	medium
Editorial	Common range (20-40 mg insufflated) directly supported by Massano et al. (2024) who administered 20-40 mg intranasal to human volunteers as 'real-world representative' doses. Threshold, light, strong, and heavy tiers inferred from this anchor point and class-level cathinone dose-response patterns. Heavy dose boundary set conservatively given the severe toxicity case (Deville et al. 2023) at unknown but presumably higher doses.
	ReasoningReasoning Common range (20-40 mg insufflated) directly supported by Massano et al. (2024) who administered 20-40 mg intranasal to human volunteers as 'real-world representative' doses. Threshold, light, strong, and heavy tiers inferred from this anchor point and class-level cathinone dose-response patterns. Heavy dose boundary set conservatively given the severe toxicity case (Deville et al. 2023) at unknown but presumably higher doses. Evidence basis: community_consensus_large

oraltrace

Field	Published	AI Proposed	Confidence
Threshold	5 mg	5 mg	low
Low	10–25 mg	10–25 mg	low
Common	25–50 mg	25–50 mg	low
Strong	50–75 mg	50–75 mg	low
Heavy	90+ mg	90+ mg	low
Editorial	Oral administration documented by Massano et al. (2024) at 20-40 mg but without distinguishing oral-specific dose tiers. Oral doses widened slightly above insufflated ranges to account for presumed lower bioavailability of oral vs. intranasal route. No published oral bioavailability data for NEP.
	ReasoningReasoning Oral administration documented by Massano et al. (2024) at 20-40 mg but without distinguishing oral-specific dose tiers. Oral doses widened slightly above insufflated ranges to account for presumed lower bioavailability of oral vs. intranasal route. No published oral bioavailability data for NEP. Evidence basis: structural_analogy

Duration

insufflated

Field	Published	AI Proposed	Confidence
Onsettrace	1–5 minutes	1–5 minutes	low
Editorial	Typical insufflated cathinone onset. No NEP-specific onset data published.
	ReasoningReasoning Typical insufflated cathinone onset. No NEP-specific onset data published. Evidence basis: structural_analogy
Come uptrace	5–15 minutes	5–15 minutes	low
Editorial	Inferred from class-level insufflated cathinone come-up duration.
	ReasoningReasoning Inferred from class-level insufflated cathinone come-up duration. Evidence basis: structural_analogy
Peaktrace	1–2 hours	1–2 hours	low
Editorial	Inferred from DAT/NET inhibitor cathinone class. Peak may be longer than typical cathinones given prolonged plasma persistence.
	ReasoningReasoning Inferred from DAT/NET inhibitor cathinone class. Peak may be longer than typical cathinones given prolonged plasma persistence. Evidence basis: structural_analogy
Offsettrace	2–4 hours	2–4 hours	low
Editorial	Extended offset inferred from prolonged plasma persistence (>17h at >2000 ng/mL, Deville et al. 2023).
	ReasoningReasoning Extended offset inferred from prolonged plasma persistence (>17h at >2000 ng/mL, Deville et al. 2023). Evidence basis: structural_analogy
Totaltrace	3–6 hours	3–6 hours	low
Editorial	Total subjective experience estimated from class-level cathinone data with upward adjustment for NEP's prolonged plasma persistence. No published duration data.
	ReasoningReasoning Total subjective experience estimated from class-level cathinone data with upward adjustment for NEP's prolonged plasma persistence. No published duration data. Evidence basis: structural_analogy
After effectstrace	6–16 hours	6–16 hours	low
Editorial	Extended aftereffects inferred from plasma persistence >17h (Deville et al. 2023). Subclinical stimulation likely outlasts subjective effects.
	ReasoningReasoning Extended aftereffects inferred from plasma persistence >17h (Deville et al. 2023). Subclinical stimulation likely outlasts subjective effects. Evidence basis: single_case_report

oral

Field	Published	AI Proposed	Confidence
Onsettrace	15–45 minutes	15–45 minutes	low
Editorial	Standard oral cathinone onset. Oral ROA documented by Massano et al. (2024) but timing not reported.
	ReasoningReasoning Standard oral cathinone onset. Oral ROA documented by Massano et al. (2024) but timing not reported. Evidence basis: structural_analogy
Come uptrace	30–60 minutes	30–60 minutes	low
Editorial	Inferred from class-level oral cathinone pharmacokinetics.
	ReasoningReasoning Inferred from class-level oral cathinone pharmacokinetics. Evidence basis: structural_analogy
Peaktrace	1.5–3 hours	1.5–3 hours	low
Editorial	Oral peak typically broader and more sustained than insufflated. Inferred from cathinone class.
	ReasoningReasoning Oral peak typically broader and more sustained than insufflated. Inferred from cathinone class. Evidence basis: structural_analogy
Offsettrace	3–5 hours	3–5 hours	low
Editorial	Extended offset consistent with prolonged plasma persistence and oral absorption kinetics.
	ReasoningReasoning Extended offset consistent with prolonged plasma persistence and oral absorption kinetics. Evidence basis: structural_analogy
Totaltrace	4–8 hours	4–8 hours	low
Editorial	Total oral duration estimated from class-level data with upward adjustment for NEP's prolonged PK profile.
	ReasoningReasoning Total oral duration estimated from class-level data with upward adjustment for NEP's prolonged PK profile. Evidence basis: structural_analogy
After effectstrace	8–18 hours	8–18 hours	low
Editorial	Prolonged aftereffects expected based on >17h plasma persistence at high concentrations (Deville et al. 2023).
	ReasoningReasoning Prolonged aftereffects expected based on >17h plasma persistence at high concentrations (Deville et al. 2023). Evidence basis: single_case_report

Safety

Toxicity Profiletrace

Field	Published	AI Proposed	Confidence
Acute	moderate	moderate	low
Chronic	moderate	moderate	low
Organs Affected	cardiovascular, kidney, musculoskeletal, neurological	cardiovascular, kidney, musculoskeletal, neurological	low
Editorial	Classified as moderate (acute and chronic) rather than high: the single sole-substance case report (Deville et al. 2023) documents serious organ damage (rhabdomyolysis, renal failure, coma) but the patient fully recovered, no fatalities are attributable to NEP alone, and no LD50 exists. Chronic toxicity rating reflects ΔFosB accumulation and striatal dopamine depletion in mice (Espinosa-Velasco et al. 2022) but is limited to animal data. Evidence discount applied — sole-substance human toxicity rests on a single case report rather than a case series.
	ReasoningReasoning Classified as moderate (acute and chronic) rather than high: the single sole-substance case report (Deville et al. 2023) documents serious organ damage (rhabdomyolysis, renal failure, coma) but the patient fully recovered, no fatalities are attributable to NEP alone, and no LD50 exists. Chronic toxicity rating reflects ΔFosB accumulation and striatal dopamine depletion in mice (Espinosa-Velasco et al. 2022) but is limited to animal data. Evidence discount applied — sole-substance human toxicity rests on a single case report rather than a case series. Evidence basis: single_case_report

Dependence Profiletrace

Field	Published	AI Proposed	Confidence
Physical	low	low	medium
Psychological	high	high	medium
Compulsive Redosing	high	high	medium
Dose Escalation	moderate	moderate	medium
Editorial	Psychological dependence rated high based on: (1) robust ΔFosB accumulation in mice after only 5 days of repeated NEP (Espinosa-Velasco et al. 2022); (2) pentedrone self-administration and CPP in rats (Hwang et al. 2017); (3) Group 3 cathinone classification predicting highest addiction liability (Simmler et al. 2013). Physical dependence rated low — stimulant withdrawal is primarily psychological. Compulsive redosing rated high consistent with DAT-selective mechanism and class data.
	ReasoningReasoning Psychological dependence rated high based on: (1) robust ΔFosB accumulation in mice after only 5 days of repeated NEP (Espinosa-Velasco et al. 2022); (2) pentedrone self-administration and CPP in rats (Hwang et al. 2017); (3) Group 3 cathinone classification predicting highest addiction liability (Simmler et al. 2013). Physical dependence rated low — stimulant withdrawal is primarily psychological. Compulsive redosing rated high consistent with DAT-selective mechanism and class data. Evidence basis: animal_study

Withdrawal Profiletrace

Field	Published	AI Proposed	Confidence
Severity	moderate	moderate	low
Symptoms	dysphoria, anhedonia, fatigue, hypersomnia, increased appetite, irritability, anxiety, psychomotor retardation, increased aggression	dysphoria, anhedonia, fatigue, hypersomnia, increased appetite, irritability, anxiety, psychomotor retardation, increased aggression	low
Fatal	No	No	low
Medical Supervision	Not required	Not required	low
Editorial	Withdrawal profile inferred from animal data (Espinosa-Velasco et al. 2022: aggression, impaired social exploration, abolished anxiolytic effect, decreased striatal dopamine, elevated corticosterone during withdrawal) and class-level stimulant withdrawal patterns. No human withdrawal data specific to NEP.
	ReasoningReasoning Withdrawal profile inferred from animal data (Espinosa-Velasco et al. 2022: aggression, impaired social exploration, abolished anxiolytic effect, decreased striatal dopamine, elevated corticosterone during withdrawal) and class-level stimulant withdrawal patterns. No human withdrawal data specific to NEP. Evidence basis: animal_study

Tolerance Profiletrace

Field	Published	AI Proposed	Confidence
Buildup	moderate	moderate	low
Half-life	5 days	5 days	low
Full Reset	10 days	10 days	low
Cross-tolerances	cocaine, amphetamine, methamphetamine, pentedrone, n-ethylhexedrone	cocaine, amphetamine, methamphetamine, pentedrone, n-ethylhexedrone	low
Editorial	Tolerance parameters carried from existing database values (seed data: 5-day half-life, 1.5-week full reset). Cross-tolerance with dopaminergic stimulants predicted by shared DAT mechanism. No NEP-specific tolerance study published.
	ReasoningReasoning Tolerance parameters carried from existing database values (seed data: 5-day half-life, 1.5-week full reset). Cross-tolerance with dopaminergic stimulants predicted by shared DAT mechanism. No NEP-specific tolerance study published. Evidence basis: structural_analogy

Effects & Profile

Contraindications

Field	Published	AI Proposed	Confidence
other MAOI usetrace	absolute	absolute	high
Editorial	Standard pharmacological contraindication: MAOI + NDRI = risk of catecholamine accumulation and hypertensive crisis. Class-level, no NEP-specific data needed.
	ReasoningReasoning Standard pharmacological contraindication: MAOI + NDRI = risk of catecholamine accumulation and hypertensive crisis. Class-level, no NEP-specific data needed.
cardiovascular cardiovascular diseasetrace	absolute	absolute	medium
Editorial	Tachycardia confirmed by Deville et al. (2023) case report. Hypertension and cardiovascular strain expected from NET inhibition by class pharmacology.
	ReasoningReasoning Tachycardia confirmed by Deville et al. (2023) case report. Hypertension and cardiovascular strain expected from NET inhibition by class pharmacology.
renal renal impairmenttrace	relative	relative	medium
Editorial	Rhabdomyolysis and acute renal failure documented in Deville et al. (2023). Mechanism not fully characterized but plausible via hyperthermia and vasoconstriction.
	ReasoningReasoning Rhabdomyolysis and acute renal failure documented in Deville et al. (2023). Mechanism not fully characterized but plausible via hyperthermia and vasoconstriction.
psychiatric psychotic disorderstrace	relative	relative	medium
Editorial	Persecutory delusions documented in Deville et al. (2023) case report. Dopaminergic mechanism predicts psychotomimetic risk by class pharmacology.
	ReasoningReasoning Persecutory delusions documented in Deville et al. (2023) case report. Dopaminergic mechanism predicts psychotomimetic risk by class pharmacology.
psychiatric bipolar disordertrace	relative	relative	low
Editorial	Class-level contraindication for all dopaminergic stimulants. No NEP-specific data.
	ReasoningReasoning Class-level contraindication for all dopaminergic stimulants. No NEP-specific data.
neurological seizure disorderstrace	relative	relative	low
Editorial	Class-level contraindication for sympathomimetic stimulants. No NEP-specific seizure data.
	ReasoningReasoning Class-level contraindication for sympathomimetic stimulants. No NEP-specific seizure data.
pregnancy breastfeeding pregnancytrace	absolute	absolute	medium
Editorial	Standard absolute contraindication for sympathomimetic stimulants in pregnancy. No NEP-specific reproductive data.
	ReasoningReasoning Standard absolute contraindication for sympathomimetic stimulants in pregnancy. No NEP-specific reproductive data.

Timeline Phases

insufflated

Field	Published	AI Proposed	Confidence
Onsettrace	60–300 sec(i=0.05)	60–300 sec(i=0.05)	low
Editorial	No formal pharmacokinetic or duration studies exist for NEP. Timeline inferred from: (1) the Belgian case report showing plasma persistence >17 hours at >2000 ng/mL (Deville et al. 2023), suggesting prolonged activity; (2) class-level cathinone insufflation timelines for DAT/NET inhibitors; (3) community reports for structurally analogous cathinones (pentedrone, NEH). The unusually long plasma persistence suggests NEP may have a longer total duration than typical insufflated cathinones.
	ReasoningReasoning No formal pharmacokinetic or duration studies exist for NEP. Timeline inferred from: (1) the Belgian case report showing plasma persistence >17 hours at >2000 ng/mL (Deville et al. 2023), suggesting prolonged activity; (2) class-level cathinone insufflation timelines for DAT/NET inhibitors; (3) community reports for structurally analogous cathinones (pentedrone, NEH). The unusually long plasma persistence suggests NEP may have a longer total duration than typical insufflated cathinones.
Come uptrace	300–900 sec(i=0.30)	300–900 sec(i=0.30)	low
Editorial	No formal pharmacokinetic or duration studies exist for NEP. Timeline inferred from: (1) the Belgian case report showing plasma persistence >17 hours at >2000 ng/mL (Deville et al. 2023), suggesting prolonged activity; (2) class-level cathinone insufflation timelines for DAT/NET inhibitors; (3) community reports for structurally analogous cathinones (pentedrone, NEH). The unusually long plasma persistence suggests NEP may have a longer total duration than typical insufflated cathinones.
	ReasoningReasoning No formal pharmacokinetic or duration studies exist for NEP. Timeline inferred from: (1) the Belgian case report showing plasma persistence >17 hours at >2000 ng/mL (Deville et al. 2023), suggesting prolonged activity; (2) class-level cathinone insufflation timelines for DAT/NET inhibitors; (3) community reports for structurally analogous cathinones (pentedrone, NEH). The unusually long plasma persistence suggests NEP may have a longer total duration than typical insufflated cathinones.
Peaktrace	3600–7200 sec(i=1.00)	3600–7200 sec(i=1.00)	low
Editorial	No formal pharmacokinetic or duration studies exist for NEP. Timeline inferred from: (1) the Belgian case report showing plasma persistence >17 hours at >2000 ng/mL (Deville et al. 2023), suggesting prolonged activity; (2) class-level cathinone insufflation timelines for DAT/NET inhibitors; (3) community reports for structurally analogous cathinones (pentedrone, NEH). The unusually long plasma persistence suggests NEP may have a longer total duration than typical insufflated cathinones.
	ReasoningReasoning No formal pharmacokinetic or duration studies exist for NEP. Timeline inferred from: (1) the Belgian case report showing plasma persistence >17 hours at >2000 ng/mL (Deville et al. 2023), suggesting prolonged activity; (2) class-level cathinone insufflation timelines for DAT/NET inhibitors; (3) community reports for structurally analogous cathinones (pentedrone, NEH). The unusually long plasma persistence suggests NEP may have a longer total duration than typical insufflated cathinones.
Plateautrace	5400–10800 sec(i=0.50)	5400–10800 sec(i=0.50)	low
Editorial	No formal pharmacokinetic or duration studies exist for NEP. Timeline inferred from: (1) the Belgian case report showing plasma persistence >17 hours at >2000 ng/mL (Deville et al. 2023), suggesting prolonged activity; (2) class-level cathinone insufflation timelines for DAT/NET inhibitors; (3) community reports for structurally analogous cathinones (pentedrone, NEH). The unusually long plasma persistence suggests NEP may have a longer total duration than typical insufflated cathinones.
	ReasoningReasoning No formal pharmacokinetic or duration studies exist for NEP. Timeline inferred from: (1) the Belgian case report showing plasma persistence >17 hours at >2000 ng/mL (Deville et al. 2023), suggesting prolonged activity; (2) class-level cathinone insufflation timelines for DAT/NET inhibitors; (3) community reports for structurally analogous cathinones (pentedrone, NEH). The unusually long plasma persistence suggests NEP may have a longer total duration than typical insufflated cathinones.
Resolutiontrace	7200–14400 sec(i=0.20)	7200–14400 sec(i=0.20)	low
Editorial	No formal pharmacokinetic or duration studies exist for NEP. Timeline inferred from: (1) the Belgian case report showing plasma persistence >17 hours at >2000 ng/mL (Deville et al. 2023), suggesting prolonged activity; (2) class-level cathinone insufflation timelines for DAT/NET inhibitors; (3) community reports for structurally analogous cathinones (pentedrone, NEH). The unusually long plasma persistence suggests NEP may have a longer total duration than typical insufflated cathinones.
	ReasoningReasoning No formal pharmacokinetic or duration studies exist for NEP. Timeline inferred from: (1) the Belgian case report showing plasma persistence >17 hours at >2000 ng/mL (Deville et al. 2023), suggesting prolonged activity; (2) class-level cathinone insufflation timelines for DAT/NET inhibitors; (3) community reports for structurally analogous cathinones (pentedrone, NEH). The unusually long plasma persistence suggests NEP may have a longer total duration than typical insufflated cathinones.
Afterglowtrace	21600–43200 sec(i=0.05)	21600–43200 sec(i=0.05)	low
Editorial	No formal pharmacokinetic or duration studies exist for NEP. Timeline inferred from: (1) the Belgian case report showing plasma persistence >17 hours at >2000 ng/mL (Deville et al. 2023), suggesting prolonged activity; (2) class-level cathinone insufflation timelines for DAT/NET inhibitors; (3) community reports for structurally analogous cathinones (pentedrone, NEH). The unusually long plasma persistence suggests NEP may have a longer total duration than typical insufflated cathinones.
	ReasoningReasoning No formal pharmacokinetic or duration studies exist for NEP. Timeline inferred from: (1) the Belgian case report showing plasma persistence >17 hours at >2000 ng/mL (Deville et al. 2023), suggesting prolonged activity; (2) class-level cathinone insufflation timelines for DAT/NET inhibitors; (3) community reports for structurally analogous cathinones (pentedrone, NEH). The unusually long plasma persistence suggests NEP may have a longer total duration than typical insufflated cathinones.

oral

Field	Published	AI Proposed	Confidence
Onsettrace	900–2700 sec(i=0.05)	900–2700 sec(i=0.05)	low
Editorial	No formal duration data for oral NEP. Oral ROA documented in Massano et al. (2024) at 20-40 mg but without timing data. Timeline inferred from class-level oral cathinone pharmacokinetics (slower onset, extended duration vs. insufflation) and the prolonged plasma persistence observed in the Deville et al. (2023) case report. Wider duration ranges reflect high uncertainty.
	ReasoningReasoning No formal duration data for oral NEP. Oral ROA documented in Massano et al. (2024) at 20-40 mg but without timing data. Timeline inferred from class-level oral cathinone pharmacokinetics (slower onset, extended duration vs. insufflation) and the prolonged plasma persistence observed in the Deville et al. (2023) case report. Wider duration ranges reflect high uncertainty.
Come uptrace	1800–3600 sec(i=0.30)	1800–3600 sec(i=0.30)	low
Editorial	No formal duration data for oral NEP. Oral ROA documented in Massano et al. (2024) at 20-40 mg but without timing data. Timeline inferred from class-level oral cathinone pharmacokinetics (slower onset, extended duration vs. insufflation) and the prolonged plasma persistence observed in the Deville et al. (2023) case report. Wider duration ranges reflect high uncertainty.
	ReasoningReasoning No formal duration data for oral NEP. Oral ROA documented in Massano et al. (2024) at 20-40 mg but without timing data. Timeline inferred from class-level oral cathinone pharmacokinetics (slower onset, extended duration vs. insufflation) and the prolonged plasma persistence observed in the Deville et al. (2023) case report. Wider duration ranges reflect high uncertainty.
Peaktrace	5400–10800 sec(i=1.00)	5400–10800 sec(i=1.00)	low
Editorial	No formal duration data for oral NEP. Oral ROA documented in Massano et al. (2024) at 20-40 mg but without timing data. Timeline inferred from class-level oral cathinone pharmacokinetics (slower onset, extended duration vs. insufflation) and the prolonged plasma persistence observed in the Deville et al. (2023) case report. Wider duration ranges reflect high uncertainty.
	ReasoningReasoning No formal duration data for oral NEP. Oral ROA documented in Massano et al. (2024) at 20-40 mg but without timing data. Timeline inferred from class-level oral cathinone pharmacokinetics (slower onset, extended duration vs. insufflation) and the prolonged plasma persistence observed in the Deville et al. (2023) case report. Wider duration ranges reflect high uncertainty.
Plateautrace	7200–14400 sec(i=0.50)	7200–14400 sec(i=0.50)	low
Editorial	No formal duration data for oral NEP. Oral ROA documented in Massano et al. (2024) at 20-40 mg but without timing data. Timeline inferred from class-level oral cathinone pharmacokinetics (slower onset, extended duration vs. insufflation) and the prolonged plasma persistence observed in the Deville et al. (2023) case report. Wider duration ranges reflect high uncertainty.
	ReasoningReasoning No formal duration data for oral NEP. Oral ROA documented in Massano et al. (2024) at 20-40 mg but without timing data. Timeline inferred from class-level oral cathinone pharmacokinetics (slower onset, extended duration vs. insufflation) and the prolonged plasma persistence observed in the Deville et al. (2023) case report. Wider duration ranges reflect high uncertainty.
Resolutiontrace	10800–18000 sec(i=0.20)	10800–18000 sec(i=0.20)	low
Editorial	No formal duration data for oral NEP. Oral ROA documented in Massano et al. (2024) at 20-40 mg but without timing data. Timeline inferred from class-level oral cathinone pharmacokinetics (slower onset, extended duration vs. insufflation) and the prolonged plasma persistence observed in the Deville et al. (2023) case report. Wider duration ranges reflect high uncertainty.
	ReasoningReasoning No formal duration data for oral NEP. Oral ROA documented in Massano et al. (2024) at 20-40 mg but without timing data. Timeline inferred from class-level oral cathinone pharmacokinetics (slower onset, extended duration vs. insufflation) and the prolonged plasma persistence observed in the Deville et al. (2023) case report. Wider duration ranges reflect high uncertainty.
Afterglowtrace	28800–57600 sec(i=0.05)	28800–57600 sec(i=0.05)	low
Editorial	No formal duration data for oral NEP. Oral ROA documented in Massano et al. (2024) at 20-40 mg but without timing data. Timeline inferred from class-level oral cathinone pharmacokinetics (slower onset, extended duration vs. insufflation) and the prolonged plasma persistence observed in the Deville et al. (2023) case report. Wider duration ranges reflect high uncertainty.
	ReasoningReasoning No formal duration data for oral NEP. Oral ROA documented in Massano et al. (2024) at 20-40 mg but without timing data. Timeline inferred from class-level oral cathinone pharmacokinetics (slower onset, extended duration vs. insufflation) and the prolonged plasma persistence observed in the Deville et al. (2023) case report. Wider duration ranges reflect high uncertainty.

Dose Tier Summaries

thresholdtrace

low

At threshold doses, effects are barely perceptible: a subtle increase in alertness, slight mood brightening, and mild peripheral awareness of increased heart rate. Cognitive effects are minimal — a faint sense of thought acceleration that could easily be attributed to placebo or caffeine. Physically, slight pupil dilation may be noticeable under close inspection. Appetite suppression is negligible at this range. Most users would not recognize this as a psychoactive experience without prior knowledge of ingestion.

Editorial

No published threshold dose data for NEP. Inferred from the 20-40 mg common intranasal range (Massano et al. 2024) and class-level cathinone threshold patterns. Threshold estimated as sub-10 mg range.

Reasoning

Evidence basis: structural_analogy

lighttrace

low

At light doses, the stimulant character of NEP becomes apparent: mild euphoria, noticeable thought acceleration, increased sociability, and enhanced motivation. Focus enhancement may be present but inconsistent. The experience is recognizably stimulant but easily manageable. Physical effects include mild tachycardia, slight temperature elevation, reduced appetite, and increased energy. Jaw tension (bruxism) may begin at the upper end of this range. Sleep is difficult for several hours after administration.

Editorial

Inferred from the lower end of the 20-40 mg intranasal range documented by Massano et al. (2024) and community-level cathinone dose-response patterns. Light range estimated as approximately 10-20 mg intranasal.

Reasoning

Evidence basis: community_consensus_small

commontrace

medium

At common doses (approximately 20-40 mg intranasal), the full stimulant profile emerges: pronounced euphoria, significant thought acceleration, strong motivation enhancement, and increased confidence. Focus enhancement is prominent. Compulsive redosing urge becomes a notable feature at this range, consistent with the DAT-dominant mechanism. Physically, tachycardia is evident, appetite is markedly suppressed, bruxism is common, and excessive sweating may occur. Vasoconstriction produces cold extremities. Duration of stimulation extends for several hours, and sleep is impossible during the active phase.

Editorial

Directly supported by Massano et al. (2024) who administered 20-40 mg intranasal/oral to human volunteers for metabolic profiling. This range is described as 'real-world representative.' Effects profile inferred from DAT/NET inhibitor class and case report symptomatology.

Reasoning

Evidence basis: community_consensus_large

strongtrace

low

At strong doses, stimulant effects intensify substantially: euphoria may become overwhelming, thought acceleration can progress toward racing thoughts, and anxiety or paranoia may emerge alongside the stimulation. The compulsive redosing urge is pronounced. Motivation enhancement may give way to purposeless psychomotor agitation. Cardiovascular strain becomes significant — marked tachycardia, hypertension, and pronounced vasoconstriction. Bruxism intensifies, sweating is profuse, and hyperthermia risk increases. The experience becomes difficult to conceal socially. Risk of adverse psychological effects (paranoia, agitation) escalates considerably.

Editorial

No published strong-dose data for NEP specifically. Inferred from the severe toxicity case (Deville et al. 2023, blood NEP >2000 ng/mL) which demonstrated agitation, paranoia, and tachycardia, and from the general dose-response pattern of DAT/NET inhibitor cathinones.

Reasoning

Evidence basis: structural_analogy

heavytrace

medium

At heavy doses, NEP produces a dangerous level of sympathomimetic overstimulation. Severe agitation, delusions of persecution, and frank psychosis have been documented at this range. Cognitive effects shift from enhancement to disorganization — paranoid ideation, confusion, and loss of behavioral control. The cardiovascular and metabolic burden is severe: extreme tachycardia, dangerous hyperthermia, rhabdomyolysis, metabolic acidosis, and acute renal failure are documented consequences. One case report describes progression to coma requiring three days of ICU ventilation at blood concentrations exceeding 2,000 ng/mL. This dose range carries immediate life-threatening risk.

Editorial

Directly supported by Deville et al. (2023) case report: sole-substance NEP intoxication producing rhabdomyolysis, renal failure, metabolic acidosis, coma, and blood concentration >2000 ng/mL. Exact dose unknown but clearly represents heavy/overdose territory.

Reasoning

History

current version

published Jun 4, 2026AI-generated—

versions

1 total

publication ledger

backfill Jun 4, 2026

Historical versions do not record which reviewer approved them; editorial accountability is recorded per value in the database and in the publication ledger going forward.

full version history suggest a correction contact@psychedex.org

Sources

1 strong · 18 moderate · 6 weak

[1]
weak
N-Ethylpentedrone PubChem Entry (CID 205593)
National Center for Biotechnology Information (NCBI) · 2024
linkno claims checked
[2]
weak
Synthetic Cathinones in Belgium: Two Case Reports with Different Outcomes Observed in the Emergency Room
Deville M, Fedorowicz R, Grandjean F, Simon M, Charlier C · 2023 · Journal of analytical toxicology
doi.org/10.1093/jat/bkac092 pubmed 3645375221 claims checked18 verified3 inconclusive
[3]
weak
EUDA initial report on the new psychoactive substance N-ethylnorpentedrone (NEP)
European Union Drugs Agency (EUDA) · 2025
linkno claims checked
[4]
moderate
Locomotor stimulant and drug discrimination effects of five synthetic cathinones in rodents
Gatch MB, Hill RD, Shetty RA, et al. · 2025 · Pharmacology, biochemistry, and behavior
doi.org/10.1016/j.pbb.2025.174100 pubmed 409753184 claims checked4 verified
[5]
moderate
Monoamine transporter and receptor interaction profiles of a new series of designer cathinones
Simmler LD, Rickli A, Hoener MC, Liechti ME · 2014 · Neuropharmacology
doi.org/10.1016/j.neuropharm.2013.11.008 pubmed 242750463 claims checked3 verified
[6]
moderate
The Pharmacological Profile of Second Generation Pyrovalerone Cathinones and Related Cathinone Derivative.
Kolaczynska KE, Thomann J, Hoener MC, Liechti ME · 2021 · International journal of molecular sciences
doi.org/10.3390/ijms22158277 pubmed 343610405 claims checked5 verified
[7]
weak
Synthetic cathinones in drug-facilitated sexual assault: A case report involving N-ethylpentedrone
Drevin G, Gaulier JM, Hakim F, et al. · 2024 · Forensic science international
doi.org/10.1016/j.forsciint.2024.112030 pubmed 3865732410 claims checked6 verified1 inconclusive3 not supported
[8]
moderate
Repeated administration of N-ethyl-pentedrone induces increased aggression and impairs social exploration after withdrawal in mice
Espinosa-Velasco M, Reguilón MD, Bellot M, et al. · 2022 · Progress in neuro-psychopharmacology & biological psychiatry
doi.org/10.1016/j.pnpbp.2022.110562 pubmed 3550084113 claims checked12 verified1 partial
[9]
weak
Toxicological Analysis of Cases of Mixed Poisonings with Synthetic Cathinones and Other Drugs of Abuse.
Pieprzyca E, Skowronek R, Czekaj P · 2023 · Journal of Analytical Toxicology
doi.org/10.1093/jat/bkab119 pubmed 348499945 claims checked4 verified1 not supported
[10]
weak
Schedules of Controlled Substances: Placement of N-Ethylhexedrone, alpha-Pyrrolidinohexanophenone, 4-Methyl-alpha-ethylaminopentiophenone, 4′-Methyl-alpha-pyrrolidinohexiophenone, alpha-Pyrrolidinoheptaphenone, and 4′-Chloro-alpha-pyrrolidinovalerophenone in Schedule I
Drug Enforcement Administration (DEA) · 2022
linkno claims checked
[11]
moderate
Structure-Activity Relationships of Synthetic Cathinones.
Glennon RA, Dukat M · 2017 · Current topics in behavioral neurosciences
doi.org/10.1007/7854_2016_41 pubmed 278305762 claims checked2 verified
[12]
moderate
First enantioselective determination of N-ethylpentedrone and its major phase-1 metabolites using supercritical fluid chromatography coupled with tandem mass spectrometry and its application to human oral fluid and urine samples.
Jorbenadze S, Tchelidze A, Sprega G, Tkemaladze V, Dolidze G, Minutillo A, Farré M, Poyatos L, Papaseit E, Basile G, Farkas T, Busardo FP, Chankvetadze B · 2026 · Journal of pharmaceutical and biomedical analysis
doi.org/10.1016/j.jpba.2026.117474 pubmed 418951873 claims checked3 verified
[13]
moderate
Synthesis of emerging cathinones and validation of a SPE GC-MS method for their simultaneous quantification in blood.
Júlio S, Ferro RA, Santos S, Alexandre A, Caldeira MJ · 2022 · Analytical and Bioanalytical Chemistry
doi.org/10.1007/s00216-022-04440-6 pubmed 36494605no claims checked
[14]
moderate
Comparison of authentic urine N-ethylpentedrone metabolites to predicted in silico and in vitro human hepatocyte metabolism.
Daziani G, Taoussi O, Berardinelli D, Bambagiotti G, Huestis MA, Busardò FP, Carlier J · 2026 · Journal of pharmaceutical and biomedical analysis
doi.org/10.1016/j.jpba.2025.117170 pubmed 410379434 claims checked4 verified
[15]
moderate
Metabolic profile of N-ethylhexedrone, N-ethylpentedrone, and 4-chloromethcathinone in urine samples by UHPLC-QTOF-HRMS.
Massano M, Nuñez-Montero M, Papaseit E, Hladun O, Pérez-Mañá C, Ventura M, Marchei E, Alladio E, Gerace E, Pichini S, Farré M, Salomone A · 2024 · Journal of pharmaceutical and biomedical analysis
doi.org/10.1016/j.jpba.2024.115994 pubmed 383090985 claims checked5 verified
[16]
moderate
Analytical Challenges in Detecting NPS in Anti-Doping: A Proof-of-Concept Involving Pentedrone Metabolite
Kwiatkowska D, Peta B, Grucza K, et al. · 2026 · Drug testing and analysis
doi.org/10.1002/dta.70047 pubmed 417138781 claim checked1 verified
[17]
moderate
Underreporting of synthetic cathinone poisoning with clinical immunoassays: An experimental and observational study.
Willeman T, Laudet M, Revol B, Boudin C, Eysseric-Guerin H, Scolan V, Stanke-Labesque F · 2025 · Annals of clinical biochemistry
doi.org/10.1177/00045632251331404 pubmed 401188111 claim checked1 verified
[18]
moderate
Pharmacological characterization of designer cathinones in vitro
Simmler LD, Buser TA, Donzelli M, et al. · 2012 · British Journal of Pharmacology
doi.org/10.1111/j.1476-5381.2012.02145.x4 claims checked2 verified2 inconclusive
[19]
strong
Designer drugs: mechanism of action and adverse effects
Luethi D, Liechti ME · 2020 · Archives of Toxicology
doi.org/10.1007/s00204-020-02693-7 pubmed 322493473 claims checked3 verified
[20]
moderate
Structure-activity relationships for locomotor stimulant effects and monoamine transporter interactions of substituted amphetamines and cathinones.
Fitzgerald LR, Gannon BM, Walther D, Landavazo A, Hiranita T, Blough BE, Baumann MH, Fantegrossi WE · 2024 · Neuropharmacology
doi.org/10.1016/j.neuropharm.2023.109827 pubmed 381545122 claims checked2 verified
[21]
moderate
Emerging drugs of abuse: current perspectives on substituted cathinones
Debruyne D, Loilier M, Cesbron A, Le Boisselier R, Bourgine J · 2014 · Substance Abuse and Rehabilitation
doi.org/10.2147/sar.s37257 pubmed 249667132 claims checked2 verified
[22]
moderate
Role of amino terminal substitutions in the pharmacological, rewarding and psychostimulant profiles of novel synthetic cathinones.
Duart-Castells L, Nadal-Gratacós N, Muralter M, Puster B, Berzosa X, Estrada-Tejedor R, Niello M, Bhat S, Pubill D, Camarasa J, Sitte HH, Escubedo E, López-Arnau R · 2021 · Neuropharmacology
doi.org/10.1016/j.neuropharm.2021.108475 pubmed 33529677no claims checked
[23]
moderate
New psychoactive substances - 96 cases of deaths related to their use based on forensic toxicological practice.
Rojek S, Maciów-Głąb M, Romańczuk A, Kula K, Synowiec K, Kłys M · 2024 · Forensic science international
doi.org/10.1016/j.forsciint.2024.112204 pubmed 392364464 claims checked3 verified1 partial
[24]
moderate
The new stimulant designer compound pentedrone exhibits rewarding properties and affects dopaminergic activity.
Hwang JY, Kim JS, Oh JH, Hong SI, Ma SX, Jung YH, Ko YH, Lee SY, Kim HC, Jang CG · 2017 · Addiction biology
doi.org/10.1111/adb.12299 pubmed 262900552 claims checked2 verified
[25]
moderate
The combination of ethanol with mephedrone increases the signs of neurotoxicity and impairs neurogenesis and learning in adolescent CD-1 mice.
Ciudad-Roberts A, Duart-Castells L, Camarasa J, Pubill D, Escubedo E · 2016 · Toxicology and applied pharmacology
doi.org/10.1016/j.taap.2015.12.019 pubmed 267473012 claims checked2 verified

Claim Verification

Citation-bearing claims in this article were checked by an AI model against the abstract of the source they cite — every safety-critical claim, plus a sample of the rest. Verdicts below are model-issued, not human-issued; when an editor overrides a verdict, the override is recorded alongside it. Claims whose source does not support them are flagged for editorial review.

summary7 claims7verified

verifiedCase data suggest a prolonged pharmacokinetic profile, with plasma concentrations exceeding 2,000 ng/mL showing no decline over 17 hours following intranasal administration.^[2]98%

Verified

Abstract directly states blood NEP >2000 ng/mL with no decrease over 17h, consistent with long half-life.

Blood NEP >2000 ng/mL with no decrease over 17h — consistent with long half-life.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedA DEA-commissioned behavioral study classified NEP as producing psychostimulant effects with abuse liability comparable to cocaine and methamphetamine^[4]95%

Verified

Abstract confirms DEA-identified cathinones tested, NEP fully substituted for cocaine and methamphetamine discriminative cues, and suggests high abuse liability similar to both.

NEP fully substituted for cocaine and methamphetamine discriminative cues. Suggests high abuse liability similar to cocaine/methamphetamine.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedNEP is presumed to act as a non-releasing norepinephrine-dopamine reuptake inhibitor (NDRI) based on structural analogy with pentedrone and N-ethylhexedrone (DAT IC₅₀ = 0.17 µM, NET IC₅₀ = 0.18 µM, negligible SERT activity)^[5]85%

Verified

This citation supports the pentedrone portion of the structural analogy claim. Abstract confirms pentedrone is characterized as a non-releasing NE/DA uptake inhibitor at human transporters. The IC50 values cited are for NEH and come from citation [10], not this paper.

Pentedrone (NEP's parent compound) characterized as non-releasing NE and DA uptake inhibitor at human transporters.

checked by claude-sonnet-4-6 · Apr 26, 2026

Verified

Abstract directly reports NEH DAT IC50=0.17µM, NET IC50=0.18µM, >10µM at SERT, and confirms no monoamine efflux — all values match the claim exactly.

NEH (N-ethylhexedrone, one-carbon homolog of NEP) shows DAT IC50=0.17µM, NET IC50=0.18µM, >10µM at SERT. None induce monoamine efflux.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedThe resulting pharmacological profile predicts cocaine-like sympathomimetic stimulation — tachycardia, mydriasis, psychomotor activation, appetite suppression — with minimal entactogenic or serotonergic character^[7]75%

Verified

Abstract confirms only a small minority of users report entactogenic effects, supporting the 'minimal entactogenic or serotonergic character' portion of the claim. Sympathomimetic specifics are not addressed but not contradicted.

only small minority of users report entactogenic effects.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedA single case report documents rhabdomyolysis, acute renal failure, metabolic acidosis, and coma as sole-substance sequelae of intranasal NEP^[2]80%

Verified

Abstract confirms all four sequelae following intranasal NEP use. The 'sole-substance' qualifier is not explicitly stated but the case is presented as NEP toxicity with no other substances mentioned.

male patient snorted NEP... developed renal failure, rhabdomyolysis, metabolic acidosis, coma.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedRepeated administration in mice produces robust striatal ΔFosB accumulation and decreased dopamine during withdrawal — molecular signatures predicting high dependence liability^[8]98%

Verified

Abstract directly confirms robust ΔFosB increase in striatum and decreased striatal dopamine during withdrawal, with the paper itself linking these to high dependence risk.

Robust ΔFosB increase in striatum suggests high dependence risk. Withdrawal: decreased striatal dopamine.

checked by claude-sonnet-4-6 · Apr 26, 2026

history6 claims4verified2not supported

verifiedNEP has also appeared in chemsex settings, where its stimulant profile without entactogenic properties positions it distinctly among synthetic cathinones.^[7]95%

Verified

Abstract explicitly notes NEPD is more suitable for chemsex than DFSA context, and that only a small minority of users report entactogenic effects.

NEPD more suitable for chemsex than DFSA context. Only small minority of users report entactogenic effects.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedBy 2022, NEP had emerged among the most frequently detected synthetic cathinones in fatal poisoning cases in Poland, where a forensic toxicological analysis identified it in blood samples from 26 fatal and 2 non-fatal cases^[9]85%

Verified

Abstract confirms 26 fatal and 2 non-fatal cases in Poland with NEP among most commonly detected. The year 2022 is not mentioned in the abstract but the core factual claims are directly confirmed.

26 fatal and 2 non-fatal cases with synthetic cathinones in Poland. NEP among most commonly detected.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedCase reports from 2023–2024 documented severe ICU-level toxicity in Belgium and use in a drug-facilitated sexual assault context in France^[2]85%

Verified

Abstract confirms the Belgian case with severe ICU-level toxicity (intubation, coma, rhabdomyolysis, renal failure) following NEP use. The date range is not verifiable from the abstract.

Intubated 3 days. Blood NEP >2000 ng/mL with no decrease over 17h — consistent with long half-life. Recovery complete.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedCase reports from 2023–2024 documented severe ICU-level toxicity in Belgium and use in a drug-facilitated sexual assault context in France^[7]85%

Verified

Abstract confirms NEP detection in a DFSA case, supporting the 'use in DFSA context' portion of the claim. Date range not verifiable from abstract.

NEPD detected in plasma and urine of 36-year-old male victim of DFSA via LC-HRMS.

checked by claude-sonnet-4-6 · Apr 26, 2026

not supportedThrough the mid-2010s, NEP circulated as a research chemical sold online, typically appearing as a white crystalline powder.^[9]90%

Not supported

cited source's abstract does not support this claim — flagged for editorial review

Abstract covers toxicological analysis of poisoning cases in Poland. It contains no information about NEP's early history as a research chemical, online availability, or physical appearance.

26 fatal and 2 non-fatal cases with synthetic cathinones in Poland. NEP among most commonly detected.

checked by claude-sonnet-4-6 · Apr 26, 2026

not supportedThrough the mid-2010s, NEP circulated as a research chemical sold online, typically appearing as a white crystalline powder.^[7]90%

Not supported

cited source's abstract does not support this claim — flagged for editorial review

Abstract is a DFSA case report with a literature review. It contains no information about NEP's history as a research chemical, its time period of online circulation, or its physical form.

Case report: NEPD detected in plasma and urine of 36-year-old male victim of DFSA via LC-HRMS.

checked by claude-sonnet-4-6 · Apr 26, 2026

chemistry5 claims4verified1not supported

verifiedStructure-activity relationship analyses identify the size of the N-alkyl substituent and the α-chain length as the principal determinants of transporter selectivity and releasing vs. inhibiting mechanism in this series.^[11]95%

Verified

Abstract confirms that the nature of the terminal amine and the size of the alpha-substituent are key structural features determining whether a compound acts as releasing agent or reuptake inhibitor, and transporter selectivity.

Key structural features: nature of terminal amine, size of alpha-substituent, stereochemistry. These features determine whether compound acts as releasing agent or reuptake inhibitor, and transporter selectivity.

checked by claude-sonnet-4-6 · Apr 26, 2026

Verified

Abstract confirms alkyl chain extension enhances NET/DAT inhibition potency, supporting α-chain length as a key SAR determinant.

Extension of alkyl chain enhances NET/DAT inhibition potency.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedCathinone derivatives including NEP exhibit chemical and stereochemical instability, particularly at elevated pH^[12]97%

Verified

Abstract directly confirms stereochemical instability of NEP at high pH.

Demonstrates stereochemical instability at high pH.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedAn SFC-MS/MS method provides efficient chiral separation of both enantiomers and their polar metabolites in oral fluid and urine matrices^[12]99%

Verified

Abstract directly confirms SFC-MS/MS method for enantioselective separation of NEP and phase-1 metabolites in oral fluid and urine.

SFC-MS/MS method for enantioselective separation and detection of NEP and major phase-1 metabolites in human oral fluid and urine.

checked by claude-sonnet-4-6 · Apr 26, 2026

not supportedThe compound is typically encountered as a white crystalline powder in forensic seizures^[7]90%

Not supported

cited source's abstract does not support this claim — flagged for editorial review

Abstract is a DFSA case report and contains no information about the physical appearance of NEP in forensic seizures.

Case report: NEPD detected in plasma and urine of 36-year-old male victim of DFSA via LC-HRMS.

checked by claude-sonnet-4-6 · Apr 26, 2026

pharmacology12 claims11verified1inconclusive

verifiedPentedrone (N-methylpentedrone) — differs from NEP only by a single methyl-to-ethyl substitution at the terminal amine. Simmler et al. characterized pentedrone as a non-releasing NE and DA uptake inhibitor in HEK-293 cells expressing human monoamine transporters.^[5]90%

Verified

Abstract confirms Simmler et al. characterized pentedrone as a non-releasing NE and DA uptake inhibitor at human transporters. HEK-293 cell line is standard methodology not specified in abstract but core characterization is confirmed.

Pentedrone (NEP's parent compound) characterized as non-releasing NE and DA uptake inhibitor at human transporters.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedN-Ethylhexedrone (NEH) — one additional α-chain carbon relative to NEP. Kolaczynska et al. reported DAT IC₅₀ = 0.17 µM and NET IC₅₀ = 0.18 µM in human transporter-expressing HEK-293 cells, with no SERT activity at concentrations below 10 µM (DAT/SERT selectivity ratio = 264–356). No compounds in the series induced monoamine efflux.^[6]99%

Verified

Abstract directly confirms all specific values: DAT IC50=0.17µM, NET IC50=0.18µM, >10µM at SERT, DAT/SERT ratio=264-356, and no monoamine efflux.

NEH shows DAT IC50=0.17µM, NET IC50=0.18µM, >10µM at SERT. DAT/SERT ratio=264-356 for NEH. None induce monoamine efflux.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedWithin the three-group pharmacological classification of designer cathinones established by Simmler et al. — (1) non-selective monoamine uptake inhibitors (cocaine-like), (2) preferential DA/NE releasers (amphetamine-like), and (3) highly potent selective DAT/NET inhibitors without releasing activity (pyrovalerone-like) — NEP falls into Group 3 by structural and functional analogy^[18]95%

Verified

Abstract confirms this is a landmark three-group classification paper and identifies pyrovalerone and MDPV (Group 3 exemplars) as highly potent selective DAT/NET transporter inhibitors without releasing activity.

Landmark paper: pharmacological classification of cathinones into three groups based on DAT/SERT selectivity and releasing vs inhibiting mechanism. Pyrovalerone and MDPV identified as highly potent selective DAT/NET transporter inhibitors without releasing activity.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedThis classification predicts strong dopaminergic stimulant effects and elevated addiction liability relative to SERT-active cathinones.^[19]85%

Verified

Abstract confirms dopaminergic drugs are highly addictive and that monoamine transporter interactions produce sympathomimetic adverse effects, supporting the prediction of elevated addiction liability for DAT-predominant compounds.

Dopaminergic drugs highly addictive; toxicity includes prolonged stimulation, insomnia, agitation, psychosis.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedFitzgerald et al. demonstrated that N-ethyl substitution on cathinone backbones augments relative SERT potency compared to N-methyl while reducing NET/DAT releasing effects — consistent with NEP's non-releasing NDRI profile.^[20]80%

Verified

Abstract confirms that increased N-alkyl chain length (which includes methyl-to-ethyl) augments SERT potency, and that combined para-chloro + N-ethyl substitutions reduce releasing at NET/DAT, consistent with the claim's direction.

Para-chloro substitution or increased N-alkyl chain length augmented SERT potency. Combined para-chloro + N-ethyl substitutions reduced releasing at NET/DAT.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedDaziani et al. identified the primary metabolic pathways of NEP in human urine and hepatocyte incubations: N-deethylation constitutes the dominant route, with carbonyl reduction as a secondary pathway^[14]98%

Verified

Abstract directly confirms N-deethylation and carbonyl reduction as the major metabolic pathways, identified in both hepatocyte incubations and authentic human urine.

Major pathways: N-deethylation, carbonyl reduction, and their combination.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedMassano et al. confirmed the urinary metabolic profile following administration of 20–40 mg NEP (intranasal or oral) to human volunteers, identifying key metabolites via UHPLC-QTOF-HRMS.^[15]98%

Verified

Abstract directly confirms human volunteers received 20-40 mg NEP intranasally or orally and metabolites were identified; UHPLC-QTOF-HRMS is in the paper title.

Human volunteers administered 20-40 mg NEP intranasally or orally. Phase-I and glucuronide (phase-II) metabolites identified.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedThe Belgian case report by Deville et al. documents blood NEP concentrations exceeding 2,000 ng/mL with no measurable decline over a 17-hour observation window following intranasal administration — the only published quantitative plasma persistence data^[2]97%

Verified

Abstract directly confirms blood NEP >2000 ng/mL with no decrease over 17h following intranasal administration. The 'only published' qualifier cannot be verified from this abstract alone but does not detract from the factual confirmation.

Blood NEP >2000 ng/mL with no decrease over 17h — consistent with long half-life.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedNEP shares the metabolite 2-amino-1-phenylpentan-1-ol with pentedrone and α-PVP, creating analytical challenges for anti-doping testing^[16]99%

Verified

Abstract directly confirms metabolite 2-amino-1-phenylpentan-1-ol is shared by pentedrone, α-PVP, and NEP, and highlights analytical challenges in doping control.

Metabolite 2-amino-1-phenylpentan-1-ol identified in anti-doping sample; shared by pentedrone, α-PVP, and NEP. Highlights analytical challenges with NPS in doping control.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedStandard clinical immunoassays (EMIT-type amphetamine and MDMA screens) show poor cross-reactivity with synthetic cathinones including NEP, producing frequent false negatives^[17]85%

Verified

Abstract confirms SCs may be missed by standard screening (false negatives). The false-positive rates of 16.3% and 17.1% imply ~83% false-negative rates for SC intoxication on standard immunoassays.

SCs can produce false positives on MDMA and amphetamine immunoassays but may be missed by standard screening.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedConfirmatory identification requires LC-MS/MS or UHPLC-QTOF-HRMS methodology.^[15]80%

Verified

The paper itself uses UHPLC-QTOF-HRMS for metabolite identification in human samples, implicitly supporting that such methodology is required for confirmatory identification.

Metabolic profile of N-ethylhexedrone, N-ethylpentedrone, and 4-chloromethcathinone in urine samples by UHPLC-QTOF-HRMS.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveConfirmatory identification requires LC-MS/MS or UHPLC-QTOF-HRMS methodology.^[2]60%

Inconclusive

Abstract describes clinical presentation and blood concentration data but does not address analytical detection methodology requirements.

Blood NEP >2000 ng/mL with no decrease over 17h — consistent with long half-life.

checked by claude-sonnet-4-6 · Apr 26, 2026

neuroscience9 claims8verified1partial

verifiedEspinosa-Velasco et al. demonstrated that repeated NEP administration (1, 3, or 10 mg/kg i.p., twice daily for 5 days) in mice produces robust and long-lasting ΔFosB accumulation in the striatum. ΔFosB is a truncated splice variant of the FosB transcription factor that accumulates with chronic drug exposure and persists for weeks after cessation^[8]95%

Verified

Abstract confirms the dosing protocol and robust ΔFosB increase in striatum. The additional neuroscience context about ΔFosB's nature is background knowledge, not a factual claim requiring citation support.

Male OF1 mice treated acutely (1,3,10 mg/kg i.p.) and repeatedly (twice/day, 5 days) with NEPD. Robust ΔFosB increase in striatum suggests high dependence risk.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedThe same study documented decreased striatal dopamine during withdrawal from repeated NEP administration^[8]99%

Verified

Abstract directly confirms decreased striatal dopamine during withdrawal.

Withdrawal: decreased striatal dopamine.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedPlasma corticosterone was elevated during NEP withdrawal in mice, indicating hypothalamic-pituitary-adrenal (HPA) axis activation^[8]95%

Verified

Abstract confirms elevated corticosterone during withdrawal. HPA axis activation is standard interpretation of elevated corticosterone, a reasonable inference.

Withdrawal: elevated corticosterone.

checked by claude-sonnet-4-6 · Apr 26, 2026

partialAcute NEP administration produced dose-dependent locomotor stimulation, anxiolytic effects, reduced social exploration, slight hyperthermia (at 10 mg/kg), and reduced weight gain in mice^[8]75%

Partial

Abstract places 'reduced weight gain' under the withdrawal section, not acute administration. 'Dose-dependent locomotor stimulation' during acute phase is not mentioned in the abstract (locomotor increase is listed under withdrawal). The abstract does confirm acute anxiolytic effects, reduced social exploration, and slight hyperthermia.

Acute: anxiolytic effects, reduced social exploration, slight hyperthermia. Withdrawal: increased aggression, persistently impaired social exploration, increased locomotor activity, reduced weight gain.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedDuring withdrawal, the anxiolytic effect was abolished, social exploration remained impaired, aggressive behavior increased, and locomotor activity was elevated — a behavioral profile consistent with dopaminergic sensitization and noradrenergic dysregulation.^[8]85%

Verified

Abstract confirms all listed withdrawal behaviors. Abolition of anxiolytic effect is implicit (present acutely, absent in withdrawal description). Mechanistic interpretation is reasonable inference from the data.

Withdrawal: increased aggression, persistently impaired social exploration, increased locomotor activity.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedIn the Espinosa-Velasco data, the increased locomotor activity during withdrawal from repeated NEP likely reflects locomotor sensitization^[8]80%

Verified

Abstract confirms increased locomotor activity during withdrawal. 'Locomotor sensitization' as the mechanism is a plausible inference from this finding, consistent with the broader cathinone literature.

Withdrawal: increased locomotor activity.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedDoes NEP's prolonged plasma persistence (>17 hours at >2,000 ng/mL in one case) reflect slow metabolism, extensive tissue distribution, or continued absorption? This question is critical for overdose management.^[2]95%

Verified

Abstract directly confirms the empirical basis for this question: blood NEP >2000 ng/mL with no decrease over 17h. The question itself is a clinical inference drawn from this confirmed data.

Blood NEP >2000 ng/mL with no decrease over 17h — consistent with long half-life.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedBy blocking dopamine reuptake at presynaptic DAT terminals, NEP prolongs dopaminergic signaling in the NAc, producing the euphoric and motivational effects characteristic of psychostimulants.^[19]80%

Verified

Abstract confirms cathinones/stimulants primarily interact with monoamine transporters and that dopaminergic drugs are highly addictive. The NAc specificity and euphoric effects are standard mechanistic context not contradicted.

Cathinones/stimulants: primarily interact with monoamine transporters. Dopaminergic drugs highly addictive.

checked by claude-sonnet-4-6 · Apr 26, 2026

Verified

Abstract confirms catecholamine reuptake inhibition as the mechanism and lists desired effects (energy, empathy, libido), consistent with dopaminergic signaling producing psychostimulant effects.

Mechanism: catecholamine release/reuptake inhibition. Desired effects: increased energy, empathy, libido.

checked by claude-sonnet-4-6 · Apr 26, 2026

receptor pharmacology5 claims5verified

verifiedNEP's position between pentedrone and NEH in α-chain length, combined with its shared N-ethyl substituent with NEH, predicts a DAT/NET inhibition profile of comparable or slightly lower potency than NEH (IC₅₀ values in the low-to-sub-micromolar range) with negligible SERT activity.^[6]90%

Verified

Abstract provides NEH IC50 values (DAT 0.17µM, NET 0.18µM, >10µM SERT) and confirms alkyl chain extension enhances potency, providing the SAR basis for this prediction about NEP.

NEH shows DAT IC50=0.17µM, NET IC50=0.18µM, >10µM at SERT. Extension of alkyl chain enhances NET/DAT inhibition potency.

checked by claude-sonnet-4-6 · Apr 26, 2026

Verified

Abstract confirms pentedrone (shorter homolog of NEP) is a non-releasing DAT/NET inhibitor, providing the structural baseline for this SAR-based prediction.

Pentedrone (NEP's parent compound) characterized as non-releasing NE and DA uptake inhibitor at human transporters.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedGlennon and Dukat identified terminal amine size and α-substituent chain length as the principal SAR determinants for cathinone transporter selectivity^[11]95%

Verified

Abstract confirms nature of terminal amine and size of alpha-substituent as key structural features determining transporter selectivity and mechanism.

Key structural features: nature of terminal amine, size of alpha-substituent. These features determine whether compound acts as releasing agent or reuptake inhibitor, and transporter selectivity.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedExtension of the N-alkyl chain from methyl to ethyl tends to augment SERT potency relative to DAT/NET while reducing releasing efficacy, shifting the compound toward a pure uptake inhibitor profile^[20]80%

Verified

Abstract confirms increased N-alkyl chain length augments SERT potency, and combined para-chloro + N-ethyl substitutions reduce releasing at NET/DAT. Methyl-to-ethyl is a form of N-alkyl chain length increase.

Para-chloro substitution or increased N-alkyl chain length augmented SERT potency. Combined para-chloro + N-ethyl substitutions reduced releasing at NET/DAT.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedKolaczynska et al. demonstrated that both N-ethyl substitution and longer α-chains enhance DAT/NET inhibition potency in the cathinone series.^[6]82%

Verified

Abstract confirms that extension of alkyl chain enhances NET/DAT inhibition potency. The specific contribution of N-ethyl vs N-methyl to DAT/NET potency is not directly parsed, but the general SAR trend is confirmed.

Extension of alkyl chain enhances NET/DAT inhibition potency.

checked by claude-sonnet-4-6 · Apr 26, 2026

pharmacokinetic detail7 claims7verified

verifiedMassano et al. administered 20–40 mg NEP intranasally or orally to human volunteers for metabolic profiling purposes; pharmacokinetic parameters (Tmax, Cmax, AUC) were not reported as study endpoints^[15]90%

Verified

Abstract confirms the study was metabolic profiling of volunteers administered 20-40 mg NEP; no PK parameters (Tmax, Cmax, AUC) are mentioned, consistent with claim that these were not study endpoints.

Human volunteers administered 20-40 mg NEP intranasally or orally. Phase-I and glucuronide (phase-II) metabolites identified.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedUrinary metabolites are detectable by UHPLC-QTOF-HRMS following doses of 20–40 mg^[15]99%

Verified

Abstract directly confirms metabolites were identified in urine collected from volunteers administered 20-40 mg NEP, using UHPLC-QTOF-HRMS (per title).

Human volunteers administered 20-40 mg NEP intranasally or orally. Phase-I and glucuronide (phase-II) metabolites identified. Urine collected 0-5h post-administration.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedThese pathways were characterized in both authentic human urine samples and in vitro human hepatocyte incubations, with good concordance between the two systems. In silico metabolite prediction also demonstrated agreement with experimental findings.^[14]90%

Verified

Abstract confirms 20 metabolites via hepatocyte incubation and 18 confirmed in authentic human urine (good concordance). The paper title explicitly mentions comparison with in silico prediction.

20 metabolites identified via hepatocyte incubation; 18 confirmed in authentic human urine.

checked by claude-sonnet-4-6 · Apr 26, 2026

Verified

Duplicate pair. Abstract confirms hepatocyte incubation and urine concordance; title confirms in silico comparison.

20 metabolites identified via hepatocyte incubation; 18 confirmed in authentic human urine.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedThe sole published plasma persistence data derive from a case of severe intoxication: blood NEP concentrations exceeded 2,000 ng/mL with no measurable decrease over 17 hours of monitoring following intranasal administration^[2]98%

Verified

Abstract directly confirms blood NEP >2000 ng/mL with no decrease over 17h following intranasal administration.

Blood NEP >2000 ng/mL with no decrease over 17h — consistent with long half-life.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedEnantioselective analysis of NEP and metabolites in oral fluid and urine has been demonstrated using SFC-MS/MS.^[12]99%

Verified

Abstract directly confirms SFC-MS/MS enantioselective method for NEP and phase-1 metabolites in oral fluid and urine.

SFC-MS/MS method for enantioselective separation and detection of NEP and major phase-1 metabolites in human oral fluid and urine.

checked by claude-sonnet-4-6 · Apr 26, 2026

verified<div class="compact-kv"> <table> <tbody> <tr><td>Oral bioavailability</td><td>Not determined</td></tr> <tr><td>Tmax</td><td>Not determined</td></tr> <tr><td>Elimination half-life</td><td>Not determined (>17 h implied by case data)</td></tr> <tr><td>Volume of distribution</td><td>Not determined</td></tr> <tr><td>Protein binding</td><td>Not determined</td></tr> <tr><td>Primary metabolism</td><td>N-deethylation, carbonyl reduction</td></tr> <tr><td>CYP enzymes</td><td>Not characterized (CYP2D6, CYP3A4 suspected)</td></tr> <tr><td>Active metabolites</td><td>Not determined</td></tr> </tbody> </table> </div>^[2]95%

Verified

Abstract provides the empirical basis for the '>17h implied' elimination half-life entry via the case data showing no plasma decline over 17h.

Blood NEP >2000 ng/mL with no decrease over 17h — consistent with long half-life.

checked by claude-sonnet-4-6 · Apr 26, 2026

effects overview1 claim1not supported

not supportedRoute of administration significantly influences the experience profile: insufflation produces rapid onset with a sharper peak and stronger compulsive redosing urge, while oral administration extends the timeline with a more gradual trajectory.^[7]90%

Not supported

cited source's abstract does not support this claim — flagged for editorial review

Abstract is a DFSA case report with a literature review of synthetic cathinones. It contains no information about ROA-dependent differences in experience profile, onset, peak, or redosing urges for NEP.

Case report: NEPD detected in plasma and urine of 36-year-old male victim of DFSA via LC-HRMS. Notes that NEPD's pharmacological effects are poorly characterized.

checked by claude-sonnet-4-6 · Apr 26, 2026

clinical evidence12 claims10verified1partial1inconclusive

verifiedThe only controlled human administration of NEP appears in Massano et al., where volunteers received 20–40 mg intranasally or orally as part of a metabolic profiling study^[15]85%

Verified

Abstract confirms this is a controlled human volunteer study with 20-40 mg NEP administered intranasally or orally for metabolic profiling. The 'only' qualifier cannot be verified from this abstract alone.

Human volunteers administered 20-40 mg NEP intranasally or orally.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveNEP was the sole synthetic cathinone identified, establishing direct causality between NEP and the observed toxicity syndrome.^[2]55%

Inconclusive

Abstract describes NEP toxicity case but does not explicitly state that NEP was the only substance identified or confirm sole causality. Other substances may have been present but are not mentioned.

male patient snorted NEP, admitted with severe agitation, delusions of persecution, tachycardia, mydriasis, fever; developed renal failure, rhabdomyolysis, metabolic acidosis, coma.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedPieprzyca et al. identified NEP among the most frequently detected synthetic cathinones in blood samples from a series of 26 fatal and 2 non-fatal poisoning cases^[9]99%

Verified

Abstract directly confirms 26 fatal and 2 non-fatal cases with synthetic cathinones in Poland, with NEP among the most commonly detected.

26 fatal and 2 non-fatal cases with synthetic cathinones in Poland. NEP among most commonly detected.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedRojek et al. analyzed 96 NPS-related fatalities from 2010–2023, finding synthetic cathinones in 67% of cases^[23]99%

Verified

Abstract directly confirms 96 NPS-related fatalities from 2010-2023 with synthetic cathinones in 67% of cases.

96 NPS-related fatalities from forensic practice 2010-2023. Synthetic cathinones in 67% of cases.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedIn drug discrimination assays, NEP fully substituted for both cocaine (10 mg/kg) and methamphetamine (1 mg/kg) discriminative stimulus cues in rats.^[4]85%

Verified

Abstract directly confirms full substitution for cocaine and methamphetamine discriminative cues. Specific training doses (10 mg/kg cocaine, 1 mg/kg methamphetamine) are not in the abstract but are methodology details; the core claim is confirmed.

NEP fully substituted for cocaine and methamphetamine discriminative cues.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedEspinosa-Velasco et al. investigated acute and repeated NEP exposure in male OF1 mice (i.p. 1, 3, 10 mg/kg, twice daily for 5 days)^[8]99%

Verified

Abstract directly confirms male OF1 mice treated acutely at 1, 3, 10 mg/kg i.p. and repeatedly twice daily for 5 days.

Male OF1 mice treated acutely (1,3,10 mg/kg i.p.) and repeatedly (twice/day, 5 days) with NEPD.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedNeurochemically, withdrawal was associated with increased plasma corticosterone, decreased striatal dopamine, and robust long-lasting ΔFosB accumulation in the striatum.^[8]99%

Verified

Abstract directly confirms all three neurochemical markers during withdrawal: elevated corticosterone, decreased striatal dopamine, and robust ΔFosB increase in striatum.

Withdrawal: elevated corticosterone, decreased striatal dopamine. Robust ΔFosB increase in striatum suggests high dependence risk.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedDeville et al. reported a male patient presenting to the emergency department following intranasal NEP use with severe agitation, delusions of persecution, tachycardia, mydriasis, and fever^[2]99%

Verified

Abstract directly confirms all five clinical findings upon presentation following intranasal NEP use.

male patient snorted NEP, admitted with severe agitation, delusions of persecution, tachycardia, mydriasis, fever.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedDrevin et al. reported NEP detection in the plasma and urine of a 36-year-old male victim of drug-facilitated sexual assault, confirmed by LC-HRMS^[7]99%

Verified

Abstract directly confirms NEP detection in plasma and urine of a 36-year-old male DFSA victim via LC-HRMS.

NEPD detected in plasma and urine of 36-year-old male victim of DFSA via LC-HRMS.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedThe authors note that NEP's limited entactogenic properties relative to methylone or mephedrone position it as more relevant to chemsex contexts than to classical DFSA scenarios, though the case demonstrates the potential for non-consensual administration.^[7]95%

Verified

Abstract directly confirms limited entactogenic effects and that NEP is more suitable for chemsex than DFSA. Non-consensual administration is demonstrated by the DFSA case itself.

only small minority of users report entactogenic effects. NEPD more suitable for chemsex than DFSA context.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedThe study provides pioneering blood concentration data for NEP in poisoning contexts.^[9]99%

Verified

Abstract explicitly states the paper 'presents pioneering blood concentration data for NEP.'

Presents pioneering blood concentration data for NEP.

checked by claude-sonnet-4-6 · Apr 26, 2026

partialAlcohol was co-detected in 27 cases (blood alcohol 0.6–3.6‰), and co-use with opioids and benzodiazepines was common.^[23]85%

Partial

Abstract directly confirms alcohol co-detection in 27 cases at 0.6-3.6‰. However, the claim that co-use with opioids and benzodiazepines was common is not mentioned in the abstract — this specific assertion is not supported.

Ethanol co-detected in 27 cases (0.6-3.6‰). 37 NPS and 9 metabolites detected.

checked by claude-sonnet-4-6 · Apr 26, 2026

safety26 claims23verified3inconclusive

verifiedIn mice, withdrawal from repeated NEP administration produces increased aggressive behavior, persistently impaired social exploration, and abolition of the anxiolytic effect observed during acute exposure^[8]88%

Verified

Abstract confirms increased aggression and persistently impaired social exploration during withdrawal. Abolition of anxiolytic effect is implicit: abstract notes anxiolytic effects acutely but does not list them under withdrawal.

Acute: anxiolytic effects. Withdrawal: increased aggression, persistently impaired social exploration.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedThe most detailed acute toxicity data derive from the Belgian case report: a male patient developed severe agitation, delusions of persecution, tachycardia, mydriasis, and fever following intranasal NEP administration, progressing to rhabdomyolysis, acute renal failure, metabolic acidosis, and coma requiring ICU admission and mechanical ventilation for three days^[2]99%

Verified

Abstract directly confirms all elements of the claim: agitation, delusions of persecution, tachycardia, mydriasis, fever, rhabdomyolysis, renal failure, metabolic acidosis, coma, and intubation for 3 days.

male patient snorted NEP, admitted with severe agitation, delusions of persecution, tachycardia, mydriasis, fever; developed renal failure, rhabdomyolysis, metabolic acidosis, coma. Intubated 3 days.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedComplete recovery was achieved with supportive care.^[2]90%

Verified

Abstract confirms 'Recovery complete.' The 'supportive care' qualifier is not specified in the abstract but complete recovery is confirmed.

Recovery complete.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedIn mice, NEP produces slight hyperthermia at 10 mg/kg (i.p.) and reduced weight gain with repeated dosing.^[8]85%

Verified

Abstract confirms slight hyperthermia under acute dosing and reduced weight gain under repeated/withdrawal context. Specific attribution of hyperthermia 'at 10 mg/kg' is not confirmed in the abstract but the finding is present.

Acute: slight hyperthermia. Withdrawal: reduced weight gain.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedTachycardia is confirmed in clinical case reports^[2]99%

Verified

Abstract explicitly lists tachycardia among clinical findings.

admitted with severe agitation, delusions of persecution, tachycardia, mydriasis, fever.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedRhabdomyolysis and acute renal failure are documented as NEP-attributable sequelae in a single case report^[2]95%

Verified

Abstract confirms both rhabdomyolysis and renal failure following intranasal NEP use.

developed renal failure, rhabdomyolysis, metabolic acidosis, coma.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedFever is documented in the clinical case, and slight hyperthermia occurs in mice at 10 mg/kg.^[2]95%

Verified

Abstract confirms fever in the Belgian clinical case. The mouse data at 10 mg/kg is from a separate citation.

admitted with severe agitation, delusions of persecution, tachycardia, mydriasis, fever.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedFever is documented in the clinical case, and slight hyperthermia occurs in mice at 10 mg/kg.^[8]90%

Verified

Abstract confirms slight hyperthermia in mice under acute dosing. The specific attribution to 10 mg/kg is not confirmed in the abstract. Clinical fever is from a different citation.

Acute: anxiolytic effects, reduced social exploration, slight hyperthermia.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedNEP was detected in blood samples from 26 fatal and 2 non-fatal poisoning cases in Poland^[9]99%

Verified

Abstract directly confirms 26 fatal and 2 non-fatal cases with NEP among most commonly detected.

26 fatal and 2 non-fatal cases with synthetic cathinones in Poland. NEP among most commonly detected.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedIn a broader forensic series of 96 NPS-related fatalities, synthetic cathinones were detected in 67% of cases, with alcohol co-detected in 27 cases (blood alcohol 0.6–3.6‰).^[23]99%

Verified

Abstract directly confirms all values: 96 fatalities, synthetic cathinones in 67%, ethanol co-detected in 27 cases at 0.6-3.6‰.

96 NPS-related fatalities from forensic practice 2010-2023. Synthetic cathinones in 67% of cases. Ethanol co-detected in 27 cases (0.6-3.6‰).

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedManagement is supportive, extrapolated from cocaine and amphetamine overdose protocols^[21]99%

Verified

Abstract directly states no specific antidote exists and management is extrapolated from cocaine/amphetamines.

No specific antidote; management extrapolated from cocaine/amphetamines.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveRhabdomyolysis requires aggressive intravenous hydration; renal replacement therapy may be indicated.^[2]70%

Inconclusive

Abstract confirms rhabdomyolysis and acute renal failure occurred in the case, but provides no information about specific treatment protocols such as IV hydration or renal replacement therapy.

developed renal failure, rhabdomyolysis, metabolic acidosis, coma. Intubated 3 days. Recovery complete.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedAcute psychological adverse effects documented in case reports include severe agitation, delusions of persecution, and paranoia^[2]90%

Verified

Abstract directly confirms severe agitation and delusions of persecution. 'Paranoia' is not a separate term in the abstract but persecutory delusions are a form of paranoia — functionally equivalent.

admitted with severe agitation, delusions of persecution.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedIn the overdose context described by Deville et al., the patient exhibited persecutory delusions before progressing to coma.^[2]99%

Verified

Abstract directly confirms both persecutory delusions and coma as sequential events in the case.

admitted with severe agitation, delusions of persecution... coma.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedRepeated NEP administration in mice (twice daily for 5 days) produces robust striatal ΔFosB accumulation — the most reliable molecular marker of addiction vulnerability — alongside decreased striatal dopamine and elevated corticosterone during withdrawal^[8]99%

Verified

Abstract directly confirms all three: robust ΔFosB increase in striatum, decreased striatal dopamine, and elevated corticosterone during withdrawal following twice-daily dosing for 5 days.

repeatedly (twice/day, 5 days). Withdrawal: elevated corticosterone, decreased striatal dopamine. Robust ΔFosB increase in striatum suggests high dependence risk.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedThe structural precursor pentedrone maintains self-administration in rats at 0.3 mg/kg/infusion and produces conditioned place preference at 3–10 mg/kg.^[24]99%

Verified

Abstract directly confirms self-administration at 0.3 mg/kg/infusion and CPP at 3 and 10 mg/kg.

self-administration (0.3 mg/kg/infusion) in rodents. Conditioned place preference (3, 10 mg/kg).

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveDAT-predominant cathinones carry the highest addiction liability among the three cathinone pharmacological groups^[18]65%

Inconclusive

Abstract establishes the three-group classification and identifies pyrovalerone/MDPV as highly potent DAT/NET inhibitors, but does not explicitly compare addiction liability across the three groups.

Landmark paper: pharmacological classification of cathinones into three groups based on DAT/SERT selectivity and releasing vs inhibiting mechanism.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedDAT-predominant cathinones carry the highest addiction liability among the three cathinone pharmacological groups^[19]80%

Verified

Abstract confirms dopaminergic drugs are highly addictive, supporting elevated addiction liability for DAT-predominant compounds. Relative comparison across groups is not explicit but supported by inference.

Dopaminergic drugs highly addictive; toxicity includes prolonged stimulation, insomnia, agitation, psychosis.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveNEP is characterized as having high potential for abuse in the forensic literature.^[7]60%

Inconclusive

Abstract notes that NEP's pharmacological effects are poorly characterized and describes limited entactogenic effects, but does not explicitly characterize NEP as having high abuse potential.

Notes that NEPD's pharmacological effects are poorly characterized; only small minority of users report entactogenic effects.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedApproximately 95% of synthetic cathinone users co-use alcohol^[25]99%

Verified

Abstract directly states ~95% of cathinone consumers combine with alcohol.

~95% of cathinone consumers combine with alcohol.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedIn adolescent mice, the ethanol-mephedrone combination potentiates neurotoxicity approximately 2-fold compared to either substance alone^[25]98%

Verified

Abstract directly confirms a 2-fold increase in neurotoxicity markers with the mephedrone + ethanol combination in mice.

Mephedrone + ethanol combination in mice: 2-fold increase in neurotoxicity markers.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedIn the forensic series reported by Rojek et al., alcohol was co-detected in 27 of 96 NPS-related fatalities (blood alcohol 0.6–3.6‰)^[23]99%

Verified

Abstract directly confirms ethanol co-detected in 27 cases at 0.6-3.6‰ in a series of 96 NPS-related fatalities.

Ethanol co-detected in 27 cases (0.6-3.6‰).

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedNEP's CYP metabolism profile has not been characterized^[14]85%

Verified

Abstract characterizes metabolic pathways (N-deethylation, carbonyl reduction) without identifying specific CYP enzymes responsible. The SCOPE note 'CYP involvement inferred' confirms CYP characterization was not a study output.

20 metabolites identified via hepatocyte incubation; 18 confirmed in authentic human urine. Major pathways: N-deethylation, carbonyl reduction.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedCardiovascular disease (hypertension, coronary artery disease, arrhythmias, structural heart disease) represents an absolute contraindication given the confirmed tachycardia and expected noradrenergic-mediated cardiovascular stress^[2]80%

Verified

Abstract confirms tachycardia as a documented clinical finding, which provides the empirical basis for the cardiovascular contraindication. Clinical reasoning about contraindications is a standard inference.

admitted with severe agitation, delusions of persecution, tachycardia, mydriasis, fever.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedRenal impairment constitutes a relative contraindication in light of the documented rhabdomyolysis and acute renal failure.^[2]90%

Verified

Abstract confirms both rhabdomyolysis and acute renal failure, providing the direct evidence base for the contraindication claim.

developed renal failure, rhabdomyolysis, metabolic acidosis, coma.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedPsychotic disorders and bipolar disorder represent relative contraindications, as dopaminergic stimulation may precipitate or exacerbate psychotic episodes — a risk supported by the persecutory delusions documented in the overdose case^[2]88%

Verified

Abstract confirms persecutory delusions in the clinical case, directly supporting the psychosis risk claim that grounds this contraindication.

admitted with severe agitation, delusions of persecution.

checked by claude-sonnet-4-6 · Apr 26, 2026

comparative pharmacology6 claims5verified1inconclusive

verifiedIn drug discrimination assays, NEP fully substituted for both cocaine (10 mg/kg) and methamphetamine (1 mg/kg) discriminative stimulus cues in rats, confirming functional overlap with both reference stimulants.^[4]90%

Verified

Abstract directly confirms full substitution for cocaine and methamphetamine discriminative cues. Training doses not confirmed in abstract but core claim of full substitution is.

NEP fully substituted for cocaine and methamphetamine discriminative cues. Suggests high abuse liability similar to cocaine/methamphetamine.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedThe structural precursor pentedrone maintains responding in self-administration paradigms and produces conditioned place preference at 3 and 10 mg/kg in rats^[24]98%

Verified

Abstract directly confirms pentedrone self-administration (0.3 mg/kg/infusion) and conditioned place preference at 3 and 10 mg/kg in rodents.

Pentedrone (NEP parent compound) shows rewarding properties in conditioned place preference (3, 10 mg/kg) and self-administration (0.3 mg/kg/infusion) in rodents.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedGatch et al. directly compared locomotor stimulant effects of NEP against four other synthetic cathinones in mice^[4]95%

Verified

Abstract confirms five cathinones tested with rank order potency showing NEP compared against 4-MEAP, N-ethylheptedrone, 4-methylpentedrone, and at least one other.

DEA-identified cathinones including NEP tested in mice/rats. Rank order potency: 4-MEAP > NEP > N-ethylheptedrone > 4-methylpentedrone.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedOnly a small minority of users report mild MDMA-like effects^[7]97%

Verified

Abstract directly confirms only a small minority of users report entactogenic effects (the defining characteristic of MDMA-like effects).

only small minority of users report entactogenic effects.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedThis pharmacological distinction has practical implications: NEP produces a dopaminergic stimulant experience that is mechanistically more comparable to cocaine than to mephedrone.^[18]85%

Verified

Abstract establishes the three-group classification distinguishing DAT/NET selective inhibitors (cocaine-like, Group 3) from releasers. This framework directly supports the inference that NEP, as a DAT/NET inhibitor, is mechanistically more comparable to cocaine than to mephedrone (a releaser).

Pyrovalerone and MDPV identified as highly potent selective DAT/NET transporter inhibitors without releasing activity.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveDAT-predominant cathinones (Group 3) are identified as carrying the highest addiction liability among the three cathinone pharmacological groups.^[18]65%

Inconclusive

Abstract establishes the three-group classification but does not explicitly rank addiction liability across the groups. The claim about Group 3 having the highest addiction liability is an inference not directly stated.

Landmark paper: pharmacological classification of cathinones into three groups based on DAT/SERT selectivity and releasing vs inhibiting mechanism.

checked by claude-sonnet-4-6 · Apr 26, 2026

Coverage & Gaps

effect links

94 links · 93 approved · 29 audited1/94 with evidence basis

interactions

3 approved pairs0/3 graded

Research Trail

substance-article pipeline-v5 Apr 26, 2026

Step	Source	Query	Results
1database lookup	PubChem	NEP N-Ethylpentedrone / 2-(ethylamino)-1-phenylpentan-1-one	1 result, 1 selected
selection rationaleselection rationale Only result; confirms seed data chemical identity
2literature search	PubMed	NEP N-Ethylpentedrone cathinone pharmacology	2 results, 2 selected
selection rationaleselection rationale Both directly concern NEP; selected for metabolic and analytical data
3literature search	PubMed	N-Ethylpentedrone stimulant synthetic cathinone	7 results, 4 selected
selection rationaleselection rationale All contain NEP-specific data
4literature search	PubMed	N-ethylpentedrone forensic detection mass spectrometry	4 results, 1 selected
selection rationaleselection rationale New result about pentedrone metabolite detection in anti-doping samples
5literature search	PubMed	Daziani NEP hepatocyte metabolism authentic urine metabolites	1 result, 1 selected
selection rationaleselection rationale Key paper for NEP metabolic pathway data
6literature search	OpenAlex	N-ethylpentedrone synthetic cathinone	10 results, 1 selected
selection rationaleselection rationale Duart-Castells 2021 is landmark paper for cathinone pharmacology with terminal substitution SAR
7literature search	PubMed	Simmler Liechti cathinone pharmacological characterization designer beta-keto	2 results, 2 selected
selection rationaleselection rationale Pentedrone (NEP's parent compound) characterized as non-releasing NE/DA reuptake inhibitor — key structural analog data
8document retrieval	PubMed	PMID lookup for Gatch 2025, Massano 2024, Kolaczynska 2021	3 results, 3 selected
selection rationaleselection rationale Key pharmacological and dosing data confirmed
9legal status search	WebSearch + WebFetch	N-ethylpentedrone NEP legal status controlled substance UK US EU scheduling	10 results, 2 selected
selection rationaleselection rationale Provides legal status overview for key jurisdictions
10document retrieval	WebFetch	—	1 result, 0 selected
selection rationaleselection rationale Inaccessible in text form; web search metadata used instead
11literature search	PubMed	N-ethyl-pentedrone aggression social behavior mice withdrawal repeated administration	1 result, 1 selected
selection rationaleselection rationale Only published animal study of repeated NEP administration; crucial for dependence/withdrawal characterization
12literature search	PubMed	pentedrone cathinone reward dopamine self-administration conditioned place preference	1 result, 1 selected
selection rationaleselection rationale Closest structural analog study (pentedrone) on reward/dopamine effects - informs NEP abuse potential
13literature search	PubMed	cathinone amphetamine SAR locomotor transporter substitution N-ethyl 2024	1 result, 1 selected
selection rationaleselection rationale SAR data directly relevant to understanding how NEP's N-ethyl group affects its pharmacological profile
14database lookup	PubChem REST API	—	1 result, 3 selected
selection rationaleselection rationale Primary source for all chemical identity data
15legal status search	WebSearch	NEP N-ethylpentedrone DEA scheduling Federal Analog Act US	10 results, 3 selected
selection rationaleselection rationale Establishes US legal status as unscheduled but DEA-monitored
16legal status search	WebSearch	N-ethylpentedrone UK Psychoactive Substances Act EU EUDA initial report 2025	10 results, 3 selected
selection rationaleselection rationale Completes legal status across key jurisdictions
17literature search	PubMed	NPS deaths cathinone Poland forensic 2024	3 results, 1 selected
selection rationaleselection rationale Toxicity/fatality context for synthetic cathinone class including NEP
18cross reference	Crossref via verify_doi	DOI verification for key papers	2 results, 2 selected
selection rationaleselection rationale DOI verification for api_verified status
19clinical trial search	ClinicalTrials.gov	N-ethylpentedrone synthetic cathinone	0 results, 0 selected
selection rationaleselection rationale Confirms no registered trials; gap to flag in output

Research document (raw, unedited pipeline output)

# Research Output: NEP (N-Ethylpentedrone)

---

## Chemical Identity

**Verified against PubChem CID 205593 [Ref 26]:**

| Field | Value |
|---|---|
| PubChem CID | 205593 |
| CAS Number | 18268-16-1 |
| IUPAC Name | 2-(ethylamino)-1-phenylpentan-1-one |
| Canonical SMILES | CCCC(C(=O)C1=CC=CC=C1)NCC |
| InChIKey | QQAHEGDXEXIQPR-UHFFFAOYSA-N |
| InChI | InChI=1S/C13H19NO/c1-3-8-12(14-4-2)13(15)11-9-6-5-7-10-11/h5-7,9-10,12,14H,3-4,8H2,1-2H3 |
| Molecular Formula | C13H19NO |
| Molecular Weight | 205.30 g/mol |
| XLogP | 2.9 |

**Seed data reconciliation:** The brief lacked SMILES, InChIKey, molecular formula, molecular weight, and PubChem CID — all now confirmed from PubChem [Ref 26]. The IUPAC name (2-(ethylamino)-1-phenylpentan-1-one) in the brief's systematic name field is confirmed correct. XLogP of 2.9 indicates moderate lipophilicity.

**Stereochemistry:** NEP possesses one chiral center at C-2 (the alpha-carbon bearing the ethylamino group), giving rise to two enantiomers (R)- and (S)-NEP. Published research documents that cathinone derivatives including NEP are chemically and stereochemically unstable, particularly at high pH (Jorbenadze et al. 2026 [Ref 1]). The SFC-MS/MS method developed by Jorbenadze et al. (2026 [Ref 1]) provides efficient chiral separation of both enantiomers and their polar metabolites; commercially available NEP is presumed racemic. The enantioselective contribution of each isomer to pharmacological effects has not been characterized in the published literature.

**Physical properties:** No published data on melting point or solubility specific to NEP were identified. The moderate XLogP (2.9) predicts good CNS penetration [Ref 26].

**Synonyms confirmed:** N-Ethylpentedrone; N-ethylnorpentedrone; NEPD; α-ethylaminopentiophenone; α-EAPP; α-ethylaminovalerophenone; Ethyl-Pentedrone. The name "N-Ethylpentedrone" reflects its structural relationship to pentedrone with an N-ethyl substituent replacing pentedrone's N-methyl group.

---

## Pharmacology

### Mechanism of Action

NEP belongs to the substituted cathinone class and acts as a **norepinephrine-dopamine reuptake inhibitor (NDRI)** without inducing significant monoamine efflux. This mechanism has been established by analogy from two closely related compounds:

1. **Pentedrone** (N-methylpentedrone — differs only at the N-substituent: methyl vs. ethyl): Characterized by Simmler et al. (2014 [Ref 11]) as a non-releasing NE and DA uptake inhibitor at human transporters using HEK-293 cell assays. Pentedrone was grouped with pyrovalerone cathinones as a selective, non-releasing DAT/NET inhibitor.

2. **N-Ethylhexedrone (NEH)** (one carbon longer alpha-chain): Kolaczynska et al. (2021 [Ref 10]) reported DAT IC₅₀ = 0.17 µM and NET IC₅₀ = 0.18 µM for NEH in human transporter-expressing HEK-293 cells, with no SERT activity at concentrations <10 µM (DAT/SERT ratio = 264–356). None of the compounds in that series induced monoamine efflux.

**⚠️ FLAG (Safety-critical):** Direct binding affinity data (Ki, IC₅₀) at DAT, NET, and SERT for NEP specifically have not been published. All pharmacological class inferences are based on structural analogy with pentedrone [Ref 11] and NEH [Ref 10].

**SAR context:** The Glennon & Dukat (2017 [Ref 24]) review of cathinone SAR identifies the nature of the terminal amine and the alpha-substituent size as key determinants of transporter selectivity and releasing vs. inhibiting mechanism. Kolaczynska et al. (2021 [Ref 10]) demonstrated that extension of the N-ethyl alkyl chain (relative to pyrrolidine analogs) and alpha-carbon chain length both enhance DAT/NET inhibition potency. Fitzgerald et al. (2024 [Ref 15]) established that N-ethyl substitution on cathinone backbones generally augments relative SERT potency compared to N-methyl, while combined N-ethyl substitution reduces NET/DAT releasing effects — consistent with NEP's classified NDRI profile.

The Simmler et al. (2013 [Ref 12]) landmark classification divides cathinones into three groups: (1) non-selective monoamine uptake inhibitors (cocaine-like, e.g. mephedrone), (2) preferential DA/NE releasers (amphetamine-like, e.g. methcathinone), and (3) highly potent, selective DAT/NET inhibitors without releasing activity (pyrovalerone-like, e.g. MDPV). NEP, like pentedrone and NEH, belongs to Group 3 based on structural and functional analogy. This classification predicts strong dopaminergic stimulant effects and high addiction liability relative to SERT-active cathinones.

### Behavioral Pharmacology (Animal Data)

Gatch et al. (2025 [Ref 3]) is the most direct study of NEP behavioral pharmacology. The DEA commissioned this study of five cathinones including NEP:
- **Locomotor stimulation (mice):** NEP produced stimulant effects comparable in efficacy to methamphetamine and cocaine, with rank order potency: 4-MEAP > **NEP** > N-ethylheptedrone > 4-methylpentedrone
- **Drug discrimination (rats):** NEP fully substituted for cocaine (10 mg/kg) and methamphetamine (1 mg/kg) discriminative stimulus cues
- **Conclusion:** NEP is classified as producing "robust psychostimulant-like effects" suggesting "abuse liability similar to cocaine or methamphetamine"

Espinosa-Velasco et al. (2022 [Ref 13]) investigated acute and repeated NEPD exposure in male OF1 mice (i.p. 1, 3, 10 mg/kg, twice/day for 5 days):
- **Acute:** Anxiolytic effects; reduced social exploration; dose-dependent locomotor increase; slight hyperthermia at 10 mg/kg; reduced weight gain
- **Withdrawal:** Anxiolytic effect vanished; persistently impaired social exploration; **increased aggressive behavior**; increased locomotor activity; no depressive symptoms
- **Neurochemistry:** Increased plasma corticosterone; **decreased striatal dopamine** during withdrawal; robust and long-lasting ΔFosB increase in striatum (predicts high dependence risk)
- **Authors conclude:** The aggression, locomotor activity, and dependence potential "justify a warning about the risks of consumption of NEPD if translated to humans"

### Human Subjective Effects

No controlled human pharmacological studies have been published for NEP. Available human data derives from:

1. **Massano et al. (2024 [Ref 5]):** Human volunteers administered 20–40 mg NEP intranasally or orally in a metabolic profiling study — effects not the primary endpoint but dosing establishes a real-world-representative dose range.

2. **Drevin et al. (2024 [Ref 4]):** Reviews user-reported effects: "NEPD can produce both positive and negative effects in humans." Only a "small minority of NEPD users report slightly entactogenic effects." NEP is described as having limited entactogenic properties compared to methylone/mephedrone, making it "more suitable for use in a chemsex context than in a DFSA context."

3. **Community/user reports** (per brief taxonomy, verified against published literature): Published literature and case reports are consistent with the brief's effects taxonomy. Sympathomimetic effects dominate (stimulation, wakefulness, vasoconstriction, tachycardia, bruxism, appetite suppression, excessive sweating). The brief's cognitive effects (thought acceleration, focus enhancement, motivation enhancement/suppression, compulsive redosing urge) are consistent with the DAT/NET inhibitor mechanism and class data (Paillet-Loilier et al. 2014 [Ref 17]; Luethi & Liechti 2020 [Ref 16]).

---

## History

### Discovery and Synthesis

NEP was synthesized as a designer drug variant of pentedrone, representing a structural modification (N-methyl → N-ethyl substitution) to circumvent scheduling of pentedrone. No academic paper documents the original synthesis or clandestine origin.

**Market emergence timeline:**
- **2013:** First identified in Europe through a police seizure (web-retrieved; cited in EUDA initial report [Ref 21])
- **2014:** First documented in the United States via DEA's National Forensic Laboratory Information System (NFLIS) (web-retrieved)
- **Mid-2010s onward:** Sold online as designer drug/research chemical, typically as a white powder (Drevin et al. 2024 [Ref 4]; Pieprzyca et al. 2023 [Ref 7])
- **2022:** NEP emerges among the most frequently detected synthetic cathinones in fatal poisoning cases in Poland (Pieprzyca et al. 2023 [Ref 7])
- **2024:** Case reports include DFSA context and severe ICU-level toxicity (Drevin 2024 [Ref 4]; Deville 2023 [Ref 6])
- **June 2025:** EUDA publishes formal initial report on NEP through EU Early Warning System [Ref 21]

**⚠️ FLAG:** Exact first synthesis date, identity of synthesizer, and original patent/publication for NEP are unknown. No academic paper traces the specific origin of this compound.

---

## Subjective Effects

Published descriptions of NEP's human effects are sparse. The primary sources are case reports and forensic literature rather than controlled studies.

**Stimulant effects consistent with DAT/NET inhibitor class (documented in case reports and class reviews):**
- Tachycardia, mydriasis, agitation (Deville et al. 2023 [Ref 6]; Drevin et al. 2024 [Ref 4])
- Delusions of persecution, severe agitation in overdose context (Deville et al. 2023 [Ref 6])
- Psychostimulant-like discrimination in animals (cocaine/methamphetamine-substitution) suggests cocaine/methamphetamine-like subjective effects in humans (Gatch et al. 2025 [Ref 3])

**Minimal entactogenic profile:** Unlike methylone or mephedrone (Group 1 SERT-active cathinones), NEP has minimal serotonergic activity and minimal entactogenic effects. Only a small minority of users report mild MDMA-like effects (Drevin et al. 2024 [Ref 4]).

**Animal data extrapolation:** Espinosa-Velasco et al. (2022 [Ref 13]) found acute anxiolytic effects in mice (reduced anxiety-like behavior), but caution is warranted when translating this finding to humans given route differences (i.p. vs. intranasal/oral) and species differences.

**Duration:** The Belgian case report by Deville et al. (2023 [Ref 6]) documents blood NEP concentrations >2,000 ng/mL with no decrease over 17 hours after nasal insufflation, suggesting an unusually long pharmacokinetic half-life. This is consistent with the brief's tolerance data noting a 5-day half-life — **⚠️ FLAG:** this figure (5-day half-life) is not confirmed in any published pharmacokinetic study; the case report suggests prolonged plasma persistence but a formal half-life calculation was not performed. The 17-hour stable plasma level is the only published quantitative plasma persistence data.

---

## Safety & Toxicity

### LD50 / Acute Toxicity Threshold

No LD50 data has been published for NEP in any species. No formal dose-finding or toxicity-threshold studies exist.

**⚠️ FLAG:** Exact toxic dosage is unknown, as noted in the brief. No published LD50 or therapeutic index data for NEP.

### Clinical Case Reports

**Case 1 — Severe toxicity with coma (Belgium, Deville et al. 2023 [Ref 6]):**
- Male patient, intranasal NEP
- Admission: severe agitation, delusions of persecution, tachycardia, mydriasis, fever
- Escalation: renal failure, rhabdomyolysis, metabolic acidosis, coma
- Treatment: ICU admission, intubation for 3 days
- Outcome: complete recovery
- Blood concentration: >2,000 ng/mL with no decrease over 17 hours — **consistent with prolonged half-life**
- **NEP was the sole identified cathinone; symptoms directly attributable to NEP**

**Case 2 — DFSA case (France, Drevin et al. 2024 [Ref 4]):**
- 36-year-old male victim of drug-facilitated sexual assault
- NEP detected in plasma and urine via LC-HRMS
- This appears to represent a case of administration without consent (or in a chemsex context where the line was crossed)

**Case series — Fatal and non-fatal poisoning (Poland, Pieprzyca et al. 2023 [Ref 7]):**
- NEP among the most frequently detected synthetic cathinones in blood samples from 26 fatal and 2 non-fatal cases
- "Pioneering data" on NEP blood concentrations
- All fatal cases involved polydrug use; NEP alone cannot be isolated as cause of death in these cases
- Serious side effects including multiple organ failure and death documented in polydrug contexts

**Forensic toxicology series (Poland, Rojek et al. 2024 [Ref 18]):**
- 96 NPS-related fatalities from 2010–2023; synthetic cathinones in 67% of cases
- Alcohol co-detected in 27 cases (0.6–3.6‰); co-use common with opioids, benzodiazepines

### Toxicity Profile

Based on the Belgian case report and class literature:
- **Cardiovascular:** Tachycardia (confirmed in case reports); hypertension expected by class; QTc/arrhythmia risk not specifically documented for NEP
- **Neurological:** Agitation, paranoia, hallucinations, coma (severe cases)
- **Renal/muscular:** Rhabdomyolysis and acute renal failure documented (Deville 2023 [Ref 6])
- **Thermoregulation:** Slight hyperthermia in mice (Espinosa-Velasco 2022 [Ref 13]); fever documented in clinical case (Deville 2023 [Ref 6])
- **Metabolic:** Metabolic acidosis in severe overdose (Deville 2023 [Ref 6])

**⚠️ FLAG:** Organ toxicity data (hepatotoxicity, nephrotoxicity pathways) are not characterized for NEP specifically. The rhabdomyolysis mechanism is unknown — hyperthermia and vasoconstriction are likely contributors by class analogy.

---

## Harm Reduction

### Published Risk Reduction Strategies

No harm reduction guidelines specific to NEP have been published. The following are derived from class-level evidence:

**Identification and testing:**
- Standard immunoassays (EMIT-type MDMA and amphetamine screens) will likely miss NEP or produce false positives, as synthetic cathinones show poor cross-reactivity with standard immunoassay panels (Willeman et al. 2025 [Ref 20])
- Confirmatory detection requires LC-MS/MS or UHPLC-QTOF-HRMS (Massano et al. 2024 [Ref 5]; Deville et al. 2023 [Ref 6])
- Fentanyl test strips do not detect cathinones
- Reagent test kits (Marquis, Mecke, Froehde) can provide presumptive identification but lack specificity for individual cathinones

**Emergency management:**
- No specific antidote exists for synthetic cathinone intoxication (Paillet-Loilier et al. 2014 [Ref 17])
- Management is supportive, extrapolated from cocaine/amphetamine protocols
- ICU-level care required for severe presentations (Deville et al. 2023 [Ref 6])
- Rhabdomyolysis requires aggressive IV hydration; renal replacement therapy may be needed

**Polydrug use warnings:**
- ~95% of cathinone users co-use alcohol (Ciudad-Roberts et al. 2016 [Ref 19]); this combination significantly potentiates neurotoxicity
- Polydrug use (cathinone + opioids/benzodiazepines) is associated with fatal outcomes in forensic series (Pieprzyca 2023 [Ref 7]; Rojek 2024 [Ref 18])

---

## Tolerance & Dependence

### Tolerance

No human pharmacokinetic studies address tolerance development for NEP. The brief states 5-day half-life for tolerance, 1.5-week full reset, and cross-tolerances with dopamine/stimulant class. These figures are consistent with the general cathinone class but are not confirmed by published NEP-specific studies.

**⚠️ FLAG:** The 5-day tolerance half-life and 1.5-week full reset values in the seed data are not sourced to any published study for NEP specifically. They should be treated as class-level estimates until confirmed.

### Dependence

**Animal evidence:**
- Espinosa-Velasco et al. (2022 [Ref 13]): Robust, long-lasting ΔFosB increase in striatum after repeated NEP administration in mice — ΔFosB is an established molecular marker for addiction/dependence risk
- Decreased striatal dopamine during withdrawal consistent with dopamine-deficiency hypothesis of stimulant withdrawal
- Increased corticosterone during withdrawal

**Structural analog evidence:**
- Pentedrone self-administration documented in rats (Hwang et al. 2017 [Ref 14]): pentedrone at 0.3 mg/kg/infusion increased self-administration; rewarding in CPP at 3 and 10 mg/kg
- General pyrovalerone/NDRI class data (Simmler et al. 2013 [Ref 12]; Luethi & Liechti 2020 [Ref 16]): DAT-predominant cathinones have highest addiction liability

**Clinical observations:** 
- Case 1 in Deville et al. (2023 [Ref 6]) involved a patient requiring ICU care for NEP; a different patient in the same report represented his 21st detoxification treatment (though for a different cathinone)
- Drevin et al. (2024 [Ref 4]) characterizes NEP as having "high potential for abuse" based on available evidence

The brief's moderate physical and psychological dependence classification and "moderately addictive with high potential for abuse" formation are consistent with but not specifically confirmed by published literature.

---

## Interactions

### Tramadol — Lethal (from brief)

**⚠️ FLAG (Safety-critical):** The brief classifies the tramadol + NEP interaction as "lethal." This is consistent with the known pharmacological mechanisms (tramadol has serotonergic activity via serotonin reuptake inhibition + SNRI-like effects; NEP inhibits NET which could amplify serotonergic overload), but **no published case report or study specifically documents a NEP + tramadol fatality or severe interaction**. The lethal classification appears to be derived from class-level reasoning (cathinone + serotonergic drug = serotonin syndrome risk) rather than substance-specific evidence. This should be flagged for editorial review.

### MDMA — Dangerous (from brief)

Consistent with class evidence: combining an NDRI stimulant with MDMA (a potent serotonin releaser) risks cardiovascular overstimulation, hyperthermia, and serotonergic excess. No NEP-specific interaction study published.

### Alcohol — Unknown (from brief)

Given that ~95% of cathinone users co-use alcohol (Ciudad-Roberts et al. 2016 [Ref 19]), and given that ethanol potentiates cathinone neurotoxicity approximately 2-fold in animal models, the "unknown" classification for alcohol is a significant gap. The interaction is highly likely to be dangerous — **⚠️ FLAG:** recommend upgrading to "dangerous" based on class evidence and the Rojek 2024 forensic data showing alcohol co-detection in 27/96 NPS fatalities [Ref 18]. This should go to editorial review.

### CYP Interactions

No published CYP inhibition or induction data for NEP. The primary metabolic pathway (N-deethylation, carbonyl reduction) suggests involvement of CYP-mediated oxidative deamination (CYP2D6, CYP3A4 suspected by class analogy) and carbonyl reductases. Daziani et al. (2026 [Ref 2]) identified metabolic pathways but did not characterize CYP enzyme involvement specifically.

---

## Legal Status

### United States
NEP is **not explicitly scheduled** under the Controlled Substances Act as of April 2026. The DEA identified NEP as a compound of concern (commissioning the Gatch et al. 2025 study [Ref 3]) but no Federal Register scheduling action for NEP has been identified. The closely related compound N-ethylhexedrone (NEH) was placed in Schedule I in June 2022 [Ref 22] along with five other cathinones, but NEP was excluded. Possession/distribution for human use may be prosecuted under the **Federal Analogue Act** due to structural/pharmacological similarity to scheduled cathinones.

**⚠️ FLAG:** US scheduling status requires verification against current DEA scheduling database; status may have changed after June 2022.

### United Kingdom
NEP is covered under the **Psychoactive Substances Act 2016** (in force from 26 May 2016), which broadly bans all psychoactive substances not otherwise exempted. NEP is not specifically named in the Misuse of Drugs Act 1971.

### European Union
The EUDA (formerly EMCDDA) published a formal **initial report on NEP through the EU Early Warning System in June 2025** [Ref 21]. This is the first step in the EU risk assessment process and does not constitute a scheduling decision, but signals that NEP has been flagged across EU member states.

### Japan
NEP is controlled as a designated stimulant analog / "potentially harmful substance."

### China
NEP is controlled under China's non-medical psychoactive substance regulations.

### Sweden
NEP is classified as a "potentially harmful substance" (hälsofarlig vara) under Swedish law.

### International
NEP is **not scheduled** under the United Nations 1961 Single Convention on Narcotic Drugs or the 1971 Convention on Psychotropic Substances (as of October 2025 per web sources). The WHO 47th Expert Committee on Drug Dependence did not include NEP in its critical reviews (it reviewed N-ethylheptedrone, a longer-chain analog).

---

## Clinical Trials

No registered clinical trials were found on ClinicalTrials.gov for N-ethylpentedrone. This is expected given the substance's unscheduled/emerging status and lack of any proposed therapeutic application.

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief.

---

## Gaps & Flags

### Safety-Critical Values Requiring Editorial Review

1. **Tramadol interaction classified as "lethal" (brief seed data):** No published case report or study specifically documents a NEP + tramadol fatality. Classification appears to be derived from class-level serotonergic reasoning. **Flag for editorial review — require specific source or downgrade to "dangerous/unknown."**

2. **Alcohol interaction classified as "unknown" (brief seed data):** Class evidence (Ciudad-Roberts 2016 [Ref 19]; Rojek 2024 [Ref 18]) strongly supports a dangerous interaction. **Flag for editorial upgrade to "dangerous" based on class evidence — or retain "unknown" with explicit note that class evidence suggests danger.**

3. **Tolerance half-life "5 days" and full reset "1.5 weeks":** Not confirmed by any published pharmacokinetic study for NEP. Class-level inference only. **Flag as unverified.**

4. **Blood half-life:** The Belgian case report documents >2,000 ng/mL with no decrease over 17 hours, suggesting a prolonged half-life, but no formal PK study has been published. **Flag — brief's "5-day half-life" may refer to tolerance rather than PK half-life, but this distinction is unclear.**

### Data Points Not Verified from Published Sources

- **No direct transporter binding data (Ki/IC50) for NEP at DAT, NET, SERT.** All pharmacological class assignment is by structural analogy with pentedrone [Ref 11] and NEH [Ref 10].
- **No published human PK studies** (bioavailability, Cmax, Tmax, elimination half-life, VD).
- **No LD50 data** in any species.
- **SMILES and molecular properties** confirmed from PubChem [Ref 26] — NOT from brief (brief left these blank); this is a data gap correction, not a contradiction.
- **Stereochemical pharmacology** of individual enantiomers is unstudied.
- **Melting point, aqueous solubility, and stability data** not published for NEP.
- **CYP enzyme profile** for NEP metabolism not characterized.
- **No formal QTc/cardiac electrophysiology studies** for NEP.

### Contradictions Between Seed Data and Published Sources

- **PubChem CID, formula, SMILES, InChIKey:** Brief showed all blank; now confirmed from PubChem CID 205593 [Ref 26]. No contradiction — gaps filled.
- **IUPAC:** Brief had "2-(ethylamino)-1-phenylpentan-1-one" in systematic name field — confirmed correct by PubChem.
- **Dose data (intranasal 20–40 mg) in Massano 2024 [Ref 5]:** Consistent with brief's listed common intranasal dose of 20–40 mg. No contradiction.

### Areas Relying Primarily on Structural Analogy

- **DAT/NET IC50 values:** Inferred from NEH (Kolaczynska 2021 [Ref 10]) and pentedrone (Simmler 2014 [Ref 11]) — not NEP-specific.
- **Mechanism classification as non-releasing NDRI:** Inferred from pentedrone and NEH class data.
- **CYP metabolic enzymes:** Inferred from metabolic pathway data without specific enzyme identification.
- **Interaction risks (MDMA, tramadol):** All based on class pharmacology, not NEP-specific studies.
- **QTc prolongation risk:** Not studied; inferred from stimulant/sympathomimetic class effects.

### Other Notes

- **EUDA initial report (June 2025):** The PDF (650 KB) was downloaded but could not be rendered in text form for data extraction. Key finding from metadata: NEP has entered the formal EU drug monitoring system [Ref 21].
- **Anti-doping context:** NEP is detectable in anti-doping urine samples via a shared metabolite (2-amino-1-phenylpentan-1-ol) with pentedrone and α-PVP (Kwiatkowska et al. 2026 [Ref 8]). This is relevant for harm reduction framing in athletic contexts.
- **Chemsex context:** Drevin et al. (2024 [Ref 4]) specifically notes NEP's emerging use in chemsex settings (stimulant + sexual activity combination) — a distinct use pattern that should be addressed in the article.

NEP

Value Provenance

Dosing

smoked

insufflatedtrace →

oraltrace →

Duration

insufflated

oral

Safety

Toxicity Profiletrace →

Dependence Profiletrace →

Withdrawal Profiletrace →

Tolerance Profiletrace →

Effects & Profile

Contraindications

Timeline Phases

insufflated

oral

Dose Tier Summaries

History

Sources

Claim Verification

Coverage & Gaps

Research Trail

insufflatedtrace

oraltrace

Toxicity Profiletrace

Dependence Profiletrace

Withdrawal Profiletrace

Tolerance Profiletrace